



Examiner
Search Strategy
and ~~Results~~ Results



10/602,142



chain nodes :

15 17 18 19 20 22 23

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

1-7 1-20 2-18 2-19 3-22 4-15 4-23 15-17

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 6-14 7-8 8-9 9-10 10-11 11-12 12-13 13-14

exact/norm bonds :

1-2 1-5 1-7 1-20 2-3 2-18 2-19 3-4 3-22 4-5 4-15 4-23 6-7 7-8 8-9 9-10 15-17

normalized bonds :

6-10 6-14 10-11 11-12 12-13 13-14

G1:O,S,CH2,SO2

G2:H,X,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:CLASS17:CLASS18:CLASS19:CLASS20:CLASS22:CLASS23:CLASS

10/602,142

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	5	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	6	MAY 11	KOREAPAT updates resume
NEWS	7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	9	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	13	JUL 07	Coverage of Research Disclosure reinstated in DWPI
NEWS	14	JUL 11	CHEMSAFE reloaded and enhanced
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:28:06 ON 13 JUL 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

McIntosh

10/602,142

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:28:20 ON 13 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2006 HIGHEST RN 892389-74-1
DICTIONARY FILE UPDATES: 12 JUL 2006 HIGHEST RN 892389-74-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10602142.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O, S, CH2, SO2

G2 H, X, Ak

Structure attributes must be viewed using STN Express query preparation.

McIntosh

10/602,142

=> s l1

SAMPLE SEARCH INITIATED 14:29:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 358 TO ITERATE

100.0% PROCESSED 358 ITERATIONS 29 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6025 TO 8295
PROJECTED ANSWERS: 257 TO 903

L2 29 SEA SSS SAM L1

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:29:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 358 TO ITERATE

100.0% PROCESSED 358 ITERATIONS 29 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6025 TO 8295
PROJECTED ANSWERS: 257 TO 903

L3 29 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:29:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7180 TO ITERATE

100.0% PROCESSED 7180 ITERATIONS 570 ANSWERS
SEARCH TIME: 00.00.02

L4 570 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.38	167.59

FILE 'CAPLUS' ENTERED AT 14:29:41 ON 13 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

McIntosh

10/602,142

FILE COVERS 1907 - 13 Jul 2006 VOL 145 ISS 3
FILE LAST UPDATED: 12 Jul 2006 (20060712/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l4

L5 47 L4

=> s l5 and (virus or hepatituc or hcv or flavivirus or viral or antiviral)

342901 VIRUS

72869 VIRUSES

355677 VIRUS

(VIRUS OR VIRUSES)

0 HEPATITUC

10892 HCV

20 HCVS

10896 HCV

(HCV OR HCVS)

1372 FLAVIVIRUS

689 FLAVIVIRUSES

1601 FLAVIVIRUS

(FLAVIVIRUS OR FLAVIVIRUSES)

158589 VIRAL

13 VIRALS

158600 VIRAL

(VIRAL OR VIRALS)

54432 ANTIVIRAL

1096 ANTIVIRALS

54650 ANTIVIRAL

(ANTIVIRAL OR ANTIVIRALS)

L6 34 L5 AND (VIRUS OR HEPATITUC OR HCV OR FLAVIVIRUS OR VIRAL OR
ANTIVIRAL)

=> d bib abs hitstr 1-34 l6

L6 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:603846 CAPLUS

TI Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of
RNA-dependent RNA viral infection

IN Maccoss, Malcolm; Olsen, David B.; Leone, Joseph; Durette, Philippe L.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006065335	A2	20060622	WO 2005-US37224	20051017
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,			

YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRAI US 2004-620743P P 20041021

US 2005-651366P P 20050209

AB The present invention provides fluorinated pyrrolo[2,3, d]pyrimidine nucleoside compds. which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such fluorinated pyrrolo[2,3-d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3- d]pyrimidine nucleoside of the present invention.

IT 443643-17-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(fluorinated pyrrolopyrimidine nucleosides for treatment of RNA-dependent RNA viral infection)

RN 443643-17-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-fluoro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:494221 CAPLUS

DN 145:8396

TI Preparation of nucleoside analogs for treating Hepatitis C and other Flaviviridae family viral infections

IN Keicher, Jesse D.; Roberts, Christopher D.; Dyatkina, Natalia B.

PA Genelabs Technologies, Inc., USA

SO U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO

DT Patent

10/602,142

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006111311	A1	20060525	US 2005-280984	20051115
PRAI	US 2004-630453P	P	20041122		
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Nucleoside analogs I, wherein Y is a bond, -CH₂-, or -O-; W-W₂ are independently H, acyl, oxyacyl, phosphonate, phosphate esters, phosphoramidate, phosphorodiamidate, phosphoramidate monoester, cyclic phosphoramidate, cyclic phosphorodiamidate, phosphoramidate diester, and -C(O)CHR₁NHR₂, where R₁ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic and a side-chain of an amino acid; or R₁ and R₂ together with the carbon and nitrogen atoms bound thereto resp. form a heterocyclic ring compns. are prepared and useful in the treatment of viral infections caused by a Flaviviridae family virus, such as Hepatitis C virus. Thus, II was prepared and tested as an antiviral agent against Hepatitis C virus in an HCV-NS5b enzyme assay (IC₅₀ = 2.6 μM).

IT 887748-02-9P 887748-03-0P 887748-04-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside analogs for treating Hepatitis C and other Flaviviridae family viral infections)

RN 887748-02-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 887748-03-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10/602,142




RN 887748-04-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 443642-29-3P 443642-32-8P 443642-33-9P
887747-99-1P 887748-00-7P 887748-01-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of nucleoside analogs for treating Hepatitis C and other
Flaviviridae family viral infections)
RN 443642-29-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-beta-D-ribofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 443642-32-8 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-
methyl-beta-D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887747-99-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 887748-00-7 CAPLUS

McIntosh

10/602,142

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 887748-01-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



L6 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:296019 CAPLUS

DN 144:312290

TI Preparation of nucleoside derivatives as antiviral, antitumor, and antidiabetic prodrug agents

IN Reddy, Raja K.; Erion, Mark D.

PA Metabasis Therapeutics, Inc., USA

SO PCT Int. Appl., 255 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006033709	A2	20060330	WO 2005-US27235	20050729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

McIntosh

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

US 2005182252 A1 20050818 US 2004-903215 20040729
 PRAI US 2004-903215 A 20040729
 US 2005-652527P P 20050211
 US 2004-544743P P 20040213
 OS MARPAT 144:312290
 GI



AB Nucleoside derivs. I, wherein X1 is O, S, SO, substituted nitrogen; B is heterocycle, nucleobase; Y is O, S, N, substituted C, CH₂; R and R1 are independently H, alkyl, alkenyl, alkynyl, R2 is H, alky, alkenyl, alkynyl, alkylamino, cycloalkyl-amino, halogen, alkoxy; R3 is H, halogen, alkyl, alkoxy, alkenyl-oxy, alkylthio, alkylcarbonyl-oxy, aryloxy-carbonyl, azido, amino, alkylamino; R4 is H, alkyl, alkenyl, alkynyl, OH, alkoxy, halogen, CN, were prepared and tested in vitro and in rats for the treatment of viral diseases including hepatitis C viral infection, cancer, diabetes, and other diseases. The activation of prodrug analogs to NMP was evaluated in the microsomal fraction of human liver. The HepDirect-carbonate prodrugs evaluated were activated to the corresponding NMP in human liver microsomes, indicating that the enzymes required for removal of both the HepDirect and the carbonate prodrug moieties are present in this reaction system. Thus, nucleoside II was prepared via coupling and hydrogen transfer reactions and tested in vitro and in rats as antiviral, antitumor, and antidiabetic prodrug agents. The oral bioavailability (OBAV) of the free nucleoside is very low (<5 %) whereas the OBAV of its carbonate prodrugs are >20 %. The compds. of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS3 serine protease.

IT 862188-61-2P 862188-65-6P 862188-67-8P
 862188-68-9P 862188-69-0P 862188-70-3P
 862188-71-4P 862188-72-5P 862188-74-7P
 862188-75-8P 862188-77-0P 862188-78-1P
 862188-79-2P 862188-80-5P 862188-81-6P
 862188-84-9P 862188-85-0P 862188-86-1P
 862188-88-3P 862188-90-7P 862188-97-4P

862189-00-2P 862189-05-7P 862189-11-5P
 862189-12-6P 862189-13-7P 862189-19-3P
 862189-21-7P 862189-22-8P 862189-23-9P
 862189-25-1P 879493-03-5P 879493-04-6P
 879493-05-7P 879493-06-8P 879493-07-9P
 879493-08-0P 879493-09-1P 879493-11-5P
 879493-13-7P 879493-14-8P 879493-15-9P
 879493-16-0P 879493-17-1P 879493-18-2P
 879493-19-3P 879493-20-6P 879493-21-7P
 879493-24-0P 879493-25-1P 879493-26-2P
 879493-27-3P 879493-28-4P 879493-30-8P
 879493-32-0P 879493-33-1P 879493-34-2P
 879493-35-3P 879493-36-4P 879493-37-5P
 879493-38-6P 879493-39-7P 879493-40-0P
 879493-41-1P 879493-42-2P 879493-43-3P
 879493-45-5P 879493-46-6P 879493-47-7P
 879493-48-8P 879493-49-9P 879493-50-2P
 879493-51-3P 879493-53-5P 879493-54-6P
 879493-55-7P 879494-08-3P 879494-09-4P
 879494-10-7P 879494-11-8P 879494-12-9P
 879494-13-0P 879494-15-2P 879494-16-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside derivs. via coupling and hydrogen transfer reactions as antiviral, antitumor, and antidiabetic prodrug agents)

RN 862188-61-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-65-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-67-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 862188-68-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-69-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-bromophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-70-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2-bromophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-71-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(5-bromo-3-pyridinyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-72-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-phenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-74-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-75-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(5-bromo-2-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862188-77-0 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-[3,5-bis(trifluoromethyl)phenyl]-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-

McIntosh

10/602,142

methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-78-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2-bromo-4-pyridinyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-79-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2,4-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-80-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-[3-(trifluoromethyl)phenyl]-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-81-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4S,5R)-2-oxido-4,5-diphenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-84-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2-bromo-5-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-85-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3,5-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-86-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3,5-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-88-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 862188-90-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(3-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 862188-97-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862189-00-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3-cyanophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 862189-05-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-chloro-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-11-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-12-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-13-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-bromo-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-beta-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-19-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(2-bromophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-beta-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862189-21-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3,5-

bis(trifluoromethyl)phenyl]-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-22-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-[3-(trifluoromethyl)phenyl]-1,3,2-dioxaphosphorinan-2-yl]- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-23-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(2,4-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862189-25-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(3-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879493-03-5 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2,5-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-62-3

CMF C21 H23 F2 N4 O7 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



McIntosh

10/602,142

RN 879493-04-6 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3-chloro-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (10:19) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-63-4

CMF C21 H23 Cl F N4 O7 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-05-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-phenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]-, trifluoroacetate (5:2) (9CI) (CA INDEX NAME)

CM 1


CRN 862188-92-9

CMF C21 H25 N4 O7 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-06-8 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, methanesulfonate (5:8) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-65-6

CMF C21 H24 Cl N4 O7 P

Absolute stereochemistry.




CM 2

CRN 75-75-2

CMF C H4 O3 S

McIntosh

10/602,142




RN 879493-07-9 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S,5R)-2-oxido-4,5-diphenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 862188-73-6

CMF C27 H29 N4 O7 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-08-0 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2α,4α,6α)-2-oxido-4,6-diphenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 862188-76-9

CMF C27 H29 N4 O7 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-09-1 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-
[(2 α ,4 β ,6 β)-2-oxido-4,6-diphenyl-1,3,2-dioxaphosphorinan-2-yl]- β -D-ribofuranosyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 862300-23-0

CMF C27 H29 N4 O7 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142



RN 879493-11-5 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4R,5R)-4-(3-chlorophenyl)-5-methoxy-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 879493-10-4

CMF C22 H26 Cl N4 O8 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-13-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4R,5S)-4-(3-chlorophenyl)-5-methoxy-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (5:11) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 879493-12-6

CMF C22 H26 Cl N4 O8 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-14-8 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-[2-(trifluoromethyl)phenyl]-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-87-2

CMF C22 H24 F3 N4 O7 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142




RN 879493-15-9 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3-bromo-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-89-4

CMF C21 H23 Br F N4 O7 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-16-0 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(2-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]-, trifluoroacetate (5:6) (9CI) (CA INDEX NAME)

CM 1


CRN 862188-91-8

CMF C20 H24 N5 O7 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-17-1 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-phenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-92-9

CMF C21 H25 N4 O7 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142




RN 879493-18-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(4-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (10:29) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-93-0

CMF C21 H24 Cl N4 O7 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-19-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2,3-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (10:11) (9CI) (CA INDEX NAME)

CM 1


CRN 862188-94-1

CMF C21 H23 F2 N4 O7 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-20-6 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2-fluoro-5-methoxyphenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-95-2

CMF C22 H26 F N4 O8 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142




RN 879493-21-7 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2-chloro-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (10:9) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-96-3

CMF C21 H23 Cl F N4 O7 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-24-0 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2-cyanophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (10:1) (9CI) (CA INDEX NAME)

CM 1


CRN 862188-98-5

CMF C22 H24 N5 O7 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-25-1 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, trifluoroacetate (5:6) (9CI) (CA INDEX NAME)

CM 1

CRN 862188-65-6

CMF C21 H24 Cl N4 O7 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2


McIntosh



RN 879493-26-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4S)-hexahydro-2-oxido-4-phenyl-4H-1,3,2-benzodioxaphosphorin-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 879493-27-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3,4-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 879493-28-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(3-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/602,142




RN 879493-30-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 879493-29-5
CMF C26 H33 N4 O7 P

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 879493-32-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 879493-31-9
CMF C25 H31 N4 O7 P

McIntosh

10/602,142


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 879493-33-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,6S)-4,4-dimethyl-2-oxido-6-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 879493-34-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(4-cyanophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 879493-35-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,6S)-6-(3-cyanophenyl)-4,4-dimethyl-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 879493-36-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(5R,7S)-7-(3-chlorophenyl)-5-oxido-4,6-dioxo-5-phosphaspiro[2.5]oct-5-yl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879493-37-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

10/602,142


chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-01-3

CMF C21 H24 Cl N4 O8 P


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 879493-38-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879493-39-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(5-bromo-2-

McIntosh

10/602,142


fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-03-5

CMF C21 H23 Br F N4 O8 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-40-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-bromophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (10:9) (9CI) (CA INDEX NAME)

CM 1


CRN 862189-04-6

CMF C21 H24 Br N4 O8 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-41-1 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(2,5-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (5:2) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-06-8

CMF C21 H23 F2 N4 O8 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142




RN 879493-42-2 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(2-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-07-9

CMF C21 H24 Cl N4 O8 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-43-3 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(2-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]-, trifluoroacetate (10:13) (9CI) (CA INDEX NAME)

CM 1


CRN 862189-51-3

CMF C20 H24 N5 O8 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-45-5 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-[3-(trifluoromethyl)phenyl]-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]-, trifluoroacetate (5:4) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 879493-44-4

CMF C22 H24 F3 N4 O8 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142




RN 879493-46-6 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 862189-01-3

CMF C21 H24 Cl N4 O8 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-47-7 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3,5-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1


CRN 862189-09-1

CMF C21 H23 F2 N4 O8 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-48-8 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3,5-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-10-4

CMF C21 H23 Cl2 N4 O8 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142




RN 879493-49-9 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-
[(2S,4R)-2-oxido-4-phenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-
ribofuranosyl]-, trifluoroacetate (10:3) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-14-8

CMF C21 H25 N4 O8 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-50-2 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-
[(2S,4R,5S)-2-oxido-4,5-diphenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-
ribofuranosyl]-, trifluoroacetate (10:13) (9CI) (CA INDEX NAME)

CM 1


CRN 862189-15-9

CMF C27 H29 N4 O8 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-51-3 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,6R)-4,4-dimethyl-1-oxido-6-phenyl-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-16-0

CMF C23 H29 N4 O8 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142




RN 879493-53-5 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(2,3-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-18-2

CMF C21 H23 F2 N4 O8 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-54-6 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3,4-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1


CRN 862189-20-6

CMF C21 H23 Cl2 N4 O8 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 879493-55-7 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(5-bromo-3-pyridinyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-24-0

CMF C20 H23 Br N5 O8 P

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

McIntosh

10/602,142



RN 879494-08-3 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 879494-07-2

CMF C21 H25 Cl N5 O7 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 879494-09-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[5-O-[(2R,4S)-4-(3,5-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 879494-10-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(3-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 879494-11-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[5-O-[(2R,6S)-6-(2,3-difluorophenyl)-4,4-dimethyl-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 879494-12-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[5-O-[(2R,4S)-4-(2,3-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

10/602,142


Absolute stereochemistry.



RN 879494-13-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[5-O-[(2R,6S)-4,4-dimethyl-2-oxido-6-phenyl-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879494-15-2 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-beta-D-ribofuranosyl]-, trifluoroacetate (10:11) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 879494-14-1

CMF C20 H25 N6 O7 P

Absolute stereochemistry.




McIntosh

10/602,142

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 879494-16-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 443642-29-3 443642-38-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of nucleoside derivs. via coupling and hydrogen transfer reactions as antiviral, antitumor, and antidiabetic prodrug agents)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 443642-38-4 CAPLUS

McIntosh

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006012078	A2	20060202	WO 2005-US21684	20050620
	WO 2006012078	A3	20060601		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-582667P	P	20040624		
	US 2004-619746P	P	20041018		
OS	MARPAT 144:192451				
GI					



I

AB Nucleoside aryl phosphoramidates I, wherein Y is (un)substituted C or N; Ar is (un)substituted Ph; R1 is hydrogen, fluoro, azido, amino, hydroxy, C1-3 alkoxy, mercapto, and C1-3 alkylthio; R2 and R3 are each independently selected from the group consisting of hydrogen, Me, C1-16 alkylcarbonyl, C2-18 alkenylcarbonyl, C1-10 alkyloxycarbonyl, C3-6 cycloalkylcarbonyl, and C3-6 cycloalkyloxycarbonyl; R4 is hydrogen, halogen, Me, azido, or amino; R5 and R6 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, C1-4 alkoxy, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, C3-6 cycloalkylamino, di(C3-6 cycloalkyl)amino, benzylamino, dibenzylamino, or C4-6 heterocycloalkyl, wherein alkyl, cycloalkyl, benzyl, and heterocycloalkyl; R7 is hydrogen, C1-5 alkyl, (un)substituted Ph or benzyl; R8 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, (un)substituted Ph or benzyl; R9 is hydrogen or Me, were prepared as precursors to inhibitors of RNA-dependent RNA viral polymerase. Nucleoside aryl phosphoramidates, I, alone or in combination with other agents active against RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection. Thus, II was prepared (no yield) and tested as an inhibitor of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection (EC50 less than 100 μ M).

IT 874883-62-2P 874883-63-3P 874883-64-4P
874883-65-5P 874883-66-6P 874883-67-7P
874883-68-8P 874883-69-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside aryl phosphoramidates for use as an inhibitors of hepatitis C virus NS5B polymerase, RNA-dependent RNA polymerase, RNA viral replication and treating RNA-dependent RNA viral infections)

RN 874883-62-2 CAPLUS

CN L-Alanine, N-[(S)-[1-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-deoxy-2-C-methyl- β -D-ribofuranos-5-O-yl]phenoxyphosphinyl]-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 874883-63-3 CAPLUS

CN L-Alanine, N-[(R)-[1-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-deoxy-2-C-methyl-β-D-ribofuranos-5-O-yl]phenoxyphosphinyl]-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 874883-64-4 CAPLUS

CN L-Alanine, N-[(R)-[1-(2-amino-1,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-deoxy-2-C-methyl-β-D-ribofuranos-5-O-yl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 874883-65-5 CAPLUS

CN L-Alanine, N-[(S)-[1-(2-amino-1,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-deoxy-2-C-methyl-β-D-ribofuranos-5-O-yl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 874883-66-6 CAPLUS

CN L-Alanine, N-[(S)-[1-deoxy-1-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-C-methyl-β-D-ribofuranos-5-O-yl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874883-67-7 CAPLUS

CN L-Alanine, N-[(R)-[1-deoxy-1-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-C-methyl-β-D-ribofuranos-5-O-yl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 874883-68-8 CAPLUS

CN L-Alanine, N-[[1-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-deoxy-2-C-methyl-β-D-ribofuranos-5-O-yl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)

10/602,142


Absolute stereochemistry.



RN 874883-69-9 CAPLUS

CN L-Alanine, N-[[1-(2-amino-5-fluoro-1,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-1-deoxy-2-C-methyl-beta-D-ribofuranos-5-O-yl]phenoxyphosphinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 443642-29-3 443642-38-4 443642-96-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of nucleoside aryl phosphoramidates for use as an inhibitors of hepatitis C virus NS5B polymerase, RNA-dependent RNA polymerase, RNA viral replication and treating RNA-dependent RNA viral infections)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




McIntosh

10/602,142

RN 443642-38-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-96-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1050841 CAPLUS

DN 143:326574

TI Preparation of nucleosides as prodrugs and antiviral agents

IN Roberts, Christopher D.; Keicher, Jesse D.; Dyatkina, Natalia B.

PA Genelabs Technologies, Inc., USA

SO U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. Ser. No. 861,311.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005215511	A1	20050929	US 2004-971477	20041021
	US 2005090463	A1	20050428	US 2004-861311	20040604
	US 2005101550	A1	20050512	US 2004-861219	20040604
	US 2006079468	A1	20060413	US 2004-861090	20040604
PRAI	US 2003-515153P	P	20031027		
	US 2004-861090	A2	20040604		
	US 2004-861219	A2	20040604		

McIntosh

10/602,142

US 2004-861311
US 2004-602815P
OS MARPAT 143:326574
GI

A2 20040604
P 20040818



AB Nucleosides I, wherein Y is bond, CH₂, O; W-W₂ are independently H, pharmaceutically acceptable prodrug; T is substituted alkyne, substituted alkene, were prepared and used for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus. Thus, 7-(2'-C-methyl-β-D-ribofuranosyl)-4-amino-5-(2'-trimethylsilylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine was prepared and tested in vitro as antiviral agent against hepatitis C virus (replicon assay, % inhibition value range 35.8 - 98.2 μM).

IT 850338-22-6P 850338-24-8P 850338-25-9P
850338-26-0P 850338-27-1P 850338-28-2P
850338-29-3P 850338-30-6P 850338-31-7P
850338-32-8P 850338-33-9P 850338-34-0P
850338-35-1P 850338-36-2P 850338-37-3P
850338-38-4P 850338-39-5P 850338-40-8P
850338-41-9P 850338-42-0P 850338-43-1P
850338-44-2P 850338-45-3P 850338-46-4P
850338-47-5P 850338-48-6P 850338-49-7P
850338-50-0P 850338-51-1P 850338-52-2P
850338-53-3P 850338-54-4P 865480-39-3P
865480-42-8P 865480-45-1P 865480-49-5P
865480-51-9P 865480-53-1P 865480-54-2P
865480-55-3P 865480-56-4P 865480-57-5P
865480-58-6P 865480-59-7P 865480-60-0P
865480-61-1P 865480-62-2P 865480-63-3P
865480-64-4P 865480-65-5P 865480-66-6P
865480-67-7P 865480-68-8P 865480-69-9P
865480-70-2P 865480-71-3P 865480-72-4P
865480-73-5P 865480-74-6P 865480-75-7P
865480-76-8P 865480-77-9P 865480-78-0P
865480-79-1P 865480-80-4P 865480-81-5P
865480-82-6P 865480-83-7P 865480-84-8P
865480-85-9P 865480-86-0P 865480-87-1P
865480-88-2P 865480-89-3P 865480-90-6P
865480-91-7P 865480-92-8P 865480-93-9P
865480-94-0P 865480-95-1P 865480-96-2P
865481-57-8P 865481-58-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

10/602,142


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleosides as prodrugs and antiviral agents)

RN 850338-22-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-24-8 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-25-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3,3-diethoxy-1-propynyl)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 850338-26-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)-5-(2-pyridiny lethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-27-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)-5-(4-pyridiny lethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 850338-28-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-methoxyphenyl)ethynyl]-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-29-3 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-30-6 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-31-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-32-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-5-(2-pyridiny lethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-5-(4-pyridinylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-34-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-methoxyphenyl)ethynyl]-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-35-1 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-36-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3,3-diethoxy-1-propynyl)-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 850338-37-3 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-38-4 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-39-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny]l]-2-C-methyl-β-D-ribofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-40-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny
1]-2-C-methyl-β-D-ribofuranosyl]-5-(2-pyridinylethynyl)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 850338-41-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny
1]-2-C-methyl-β-D-ribofuranosyl]-5-(4-pyridinylethynyl)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 850338-42-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny]l]-2-C-methyl-β-D-ribofuranosyl]-5-[(4-methoxyphenyl)ethynyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 850338-43-1 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphiny]l]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 850338-44-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3,3-diethoxy-1-propynyl)-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-45-3 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850338-46-4 CAPLUS


CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, (9CI) (CA INDEX NAME)

McIntosh

10/602,142

1-hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-47-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-48-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-(2-pyridinyne-1-ylethynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-49-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-(4-pyridinyldethynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-50-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-[(4-methoxyphenyl)ethynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-51-1 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-52-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3,3-diethoxy-1-propynyl)-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 850338-53-3 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-54-4 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865480-39-3 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-beta-D-ribofuranosyl)-

McIntosh

10/602,142

5-(phenylethynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-42-8 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-45-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(1Z)-2-methoxyethenyl]-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 865480-49-5 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethenyl-7-(2-C-methyl- β -D-

McIntosh

10/602,142

ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-51-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 865480-53-1 CAPLUS

CN Boronic acid, 3-[4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh


10/602,142

RN 865480-54-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-, hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 865480-55-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-5-(phenylethynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-56-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]-5-(phenylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 865480-57-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-58-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. .



RN 865480-59-7 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-60-0 CAPLUS

McIntosh

10/602,142

CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 865480-61-1 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-62-2 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 865480-63-3 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-64-4 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-65-5 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-66-6 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-67-7 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865480-68-8 CAPLUS


CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-ethyl ester (9CI) (CA INDEX NAME)

McIntosh

10/602,142

d[pyrimidin-5-yl]-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-69-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-fluorophenyl)ethynyl]-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-70-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-methylphenyl)ethynyl]-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 865480-71-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-fluorophenyl)ethynyl]-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-72-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-methylphenyl)ethynyl]-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 865480-73-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny
1]-2-C-methyl-beta-D-ribofuranosyl]-5-(phenylethynyl)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 865480-74-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-fluorophenyl)ethynyl]-7-[5-O-
[hydroxy(phosphonooxy)phosphiny]l]-2-C-methyl-beta-D-ribofuranosyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 865480-75-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny
1]-2-C-methyl-β-D-ribofuranosyl]-5-[(4-methylphenyl)ethynyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 865480-76-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-fluorophenyl)ethynyl]-7-[5-O-
[hydroxy[hydroxy(phosphonooxy)phosphinyloxy]phosphinyloxy]-2-C-methyl-
β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 865480-77-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-5-[(4-methylphenyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-78-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethenyl-7-(2-C-methyl-5-O-phosphono-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 865480-79-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(1Z)-2-methoxyethenyl]-7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865480-80-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethenyl-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 865480-81-5 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-[(1Z)-2-methoxyethenyl]- (9CI)

McIntosh

10/602,142

(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 865480-82-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethenyl-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-83-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-5-[(1Z)-2-methoxyethenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


10/602,142



RN 865480-84-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-85-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-, hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 865480-86-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl- β -D-ribofuranosyl]-, hydrazone (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.
Double bond geometry unknown.



RN 865480-87-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-, hydrazone (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 865480-88-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-(2-C-methyl-5-O-phosphono-beta-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




McIntosh

10/602,142

RN 865480-89-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 865480-90-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 865480-91-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[bis(1-methylethoxy)methyl]-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 865480-92-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[bis(1-methylethoxy)methyl]-7-[5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-93-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[bis(1-methylethoxy)methyl]-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-94-0 CAPLUS

CN Boronic acid, [4-amino-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 865480-95-1 CAPLUS

CN Boronic acid, [4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865480-96-2 CAPLUS

CN Boronic acid, [4-amino-7-[5-O-[hydroxy([hydroxy(phosphonooxy)phosphinyl]oxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh


10/602,142

RN 865481-57-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(1E)-2-methoxyethenyl]-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 865481-58-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[bis(1-methylethoxy)methyl]-7-[2-C-methyl-5-O-phosphono-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 443642-29-3


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of nucleosides as prodrugs and antiviral agents)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/602,142



IT 847551-25-1P 847551-48-8P 847551-49-9P

850338-23-7P 851387-62-7P 865480-46-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nucleosides as prodrugs and antiviral agents)

RN 847551-25-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-beta-D-ribofuranosyl]-4-chloro-5-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-48-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-iodo-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 847551-49-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-iodo-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-23-7 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-62-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865480-46-2 CAPLUS

McIntosh

10/602,142

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1050840 CAPLUS

DN 143:326573

TI Methods for preparing 7-(2'-substituted- β -D-ribofuranosyl)-4-(NR₂R₃)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives as antiviral agents

IN Roberts, Christopher D.; Ketcher, Jesse D.; Dyatkina, Natalia B.

PA Genelabs Technologies, Inc., USA


SO U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 861,311.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005215510	A1	20050929	US 2004-970641	20041020
	US 2005090463	A1	20050428	US 2004-861311	20040604
	US 2006079468	A1	20060413	US 2004-861090	20040604
PRAI	US 2003-515153P	P	20031027		
	US 2004-861090	A2	20040604		
	US 2004-861311	A2	20040604		
	US 2004-602815P	P	20040818		
OS	CASREACT 143:326573; MARPAT 143:326573				
GI					



McIntosh

AB 7-(2'-Substituted- β -D-ribofuranosyl)-4-(NR₂R₃)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivs. I, wherein R₁ is alkyl, alkenyl, alkynyl; R₂ and R₃ are independently H, alkyl, amino, OH, alkoxy, formyl, acyl; NR₂R₃ form heterocyclic, were prepared as antiviral agents. These compds. are useful in treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus (IC₅₀ ranges from 0.09 to >50 μ M). Thus, I (R₁ = Me, R₂ = R₃ = H) was prepared and tested in vitro as antiviral agent (IC₅₀ = 0.09 μ M).

IT 677299-09-1P 677299-10-4P 851387-62-7P
851387-69-4P 851387-70-7P 851387-71-8P
851387-72-9P 865365-76-0P 865365-77-1P
865365-78-2P 865365-79-3P 865365-80-6P
865365-81-7P 865365-82-8P 865365-83-9P
865365-84-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(methods for preparing 7-(2'-substituted- β -D-ribofuranosyl)-4-(NR₂R₃)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivs. as antiviral agents)

RN 677299-09-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro-5-[(trimethylsilyl)ethynyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 677299-10-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 851387-62-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-69-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)- 5-(1-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-70-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(1-butynyl)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 851387-71-8 CAPLUS

CN 2-Propyn-1-ol, 3-[4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-72-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3-amino-1-propynyl)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865365-76-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 865365-77-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865365-78-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 865365-79-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865365-80-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-5-(3,3-diethoxy-1-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 865365-81-7 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 865365-82-8 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 865365-83-9 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865365-84-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-5-(phenylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh



IT 847551-25-1P 847551-48-8P 847551-49-9P
850338-22-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(methods for preparing 7-(2'-substituted-β-D-ribofuranosyl)-4-(NR₂R₃)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivs. as antiviral agents)

RN 847551-25-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-48-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-iodo-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 847551-49-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-iodo-7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-22-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-beta-D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:824501 CAPLUS

DN 143:212123

TI Preparation of 2'-C-methyl nucleoside derivatives and their uses for the treatment of hepatitis C viral infection

IN Reddy, K. Raja; Erion, Mark D.

PA USA

McIntosh

10/602,142

SO U.S. Pat. Appl. Publ., 84 pp.



CODEN: USXXEQ

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005182252	A1	20050818	US 2004-903215	20040729
	WO 2005084192	A2	20050815	WO 2005-US4447	20050214
	WO 2005084192	A3	20060511		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MD, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	WO 2006033709	A2	20060330	WO 2005-US27235	20050729
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-544743P	P	20040213		
	US 2004-903215	A	20040729		
	US 2005-652527P	P	20050211		
OS	MARPAT 143:212123				
GI					



AB 2'-C-Me nucleosides I, wherein B is purine nucleobase; V is monocyclic aryl, monocyclic heteroaryl; W and W' are independently monocyclic aryl, monocyclic heteroaryl, H, alkyl, heterocycloalkyl, aralkyl; Z is CN, acyl, amide, carboxylate, sulfonyl, sulfonamide, OH, sulfide, alkyl, aryl, heterocycloalkyl, aralkyl, thio-ester; V and Z are connected via an addnl. 3-5 atoms to form a cyclic group optionally containing hetero-atom; Z and W are connected via an addnl. 3-5 atoms to form a cyclic group optionally containing hetero-atom; W and W' are connected via an addnl. 2-5 atoms to form a cyclic group optionally containing 0-2 hetero-atoms, were prepared and used for the treatment of hepatitis C viral infection. Thus, nucleoside II was prepared and tested in mice as hepatitis C antiviral agent. The prodrug analogs are tested for activation in human liver microsomes and in rat liver microsomes activation (250 μ M). Nucleoside analogs and their prodrugs were evaluated for their ability to generate NTPs in freshly isolated rat hepatocytes. It is generally accepted that the NTP (0.1-160 nmol/g) form of a nucleoside is the active antiviral agent.

IT 862188-61-2P 862188-62-3P 862188-63-4P
 862188-64-5P 862188-65-6P 862188-66-7P
 862188-67-8P 862188-68-9P 862188-69-0P
 862188-70-3P 862188-71-4P 862188-72-5P
 862188-73-6P 862188-74-7P 862188-75-8P
 862188-76-9P 862188-77-0P 862188-78-1P
 862188-79-2P 862188-80-5P 862188-81-6P
 862188-82-7P 862188-83-8P 862188-84-9P
 862188-85-0P 862188-86-1P 862188-87-2P
 862188-88-3P 862188-89-4P 862188-90-7P
 862188-91-8P 862188-92-9P 862188-93-0P
 862188-94-1P 862188-95-2P 862188-96-3P
 862188-97-4P 862188-98-5P 862188-99-6P
 862189-00-2P 862189-01-3P 862189-02-4P
 862189-03-5P 862189-04-6P 862189-05-7P
 862189-06-8P 862189-07-9P 862189-08-0P
 862189-09-1P 862189-10-4P 862189-11-5P
 862189-12-6P 862189-13-7P 862189-14-8P
 862189-15-9P 862189-16-0P 862189-17-1P

10/602,142

862189-18-2P 862189-19-3P 862189-20-6P
862189-21-7P 862189-22-8P 862189-23-9P
862189-24-0P 862189-25-1P 862189-38-6P
862189-45-5P 862189-46-6P 862189-51-3P
862190-46-3P 862300-23-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 2'-C-Me nucleoside derivs. and their uses for the treatment
of hepatitis C viral infection)

RN 862188-61-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3-chlorophenyl)-2-
oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-62-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2,5-difluorophenyl)-2-
oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862188-63-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3-chloro-4-
fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-
ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 862188-64-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,6R)-4,4-dimethyl-2-oxido-6-phenyl-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-65-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862188-66-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

McIntosh


10/602,142

CM 1

CRN 862188-65-6

CMF C21 H24 Cl N4 O7 P


Absolute stereochemistry.



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862188-67-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 862188-68-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 862188-69-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-bromophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-70-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2-bromophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862188-71-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(5-bromo-3-pyridinyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-(9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 862188-72-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-phenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-73-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S,5R)-2-oxido-4,5-diphenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862188-74-7 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2-chlorophenyl)-2-oxido-4,5-diphenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

McIntosh

10/602,142

oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-75-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(5-bromo-2-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-76-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2 α ,4 α ,6 α)-2-oxido-4,6-diphenyl-1,3,2-dioxaphosphorinan-2-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862188-77-0 CAPLUS

McIntosh

10/602,142

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-[3,5-bis(trifluoromethyl)phenyl]-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-78-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2-bromo-4-pyridinyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-79-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2,4-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-80-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-[3-(trifluoromethyl)phenyl]-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-81-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4S,5R)-2-oxido-4,5-diphenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-82-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4R,5R)-4-(2-chlorophenyl)-5-methoxy-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-83-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4R,5S)-4-(2-chlorophenyl)-5-methoxy-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-84-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(2-bromo-5-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-85-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3,5-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-86-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3,5-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-87-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-[2-(trifluoromethyl)phenyl]-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-88-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-89-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3-bromo-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-90-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(3-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-91-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(2-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-92-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-phenyl-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-93-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(4-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-94-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2,3-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-95-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2-fluoro-5-methoxyphenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-96-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2-chloro-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-97-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862188-98-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(2-cyanophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862188-99-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-hexahydro-2-oxido-4-phenyl-4H-1,3,2-benzodioxaphosphorin-2-yl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-00-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2S,4R)-4-(3-cyanophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862189-01-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-02-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-03-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(5-bromo-2-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862189-04-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-bromophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-05-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-chloro-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-06-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(2,5-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862189-07-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(2-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-08-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-[2-(trifluoromethyl)phenyl]-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-09-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3,5-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862189-10-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3,5-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-11-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-12-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862189-13-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4S)-4-(3-bromo-4-fluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-14-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-phenyl-1,3,2-dioxaphosphorinan-2-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-15-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2S,4R,5S)-2-oxido-4,5-diphenyl-1,3,2-dioxaphosphorinan-2-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862189-16-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,6R)-4,4-dimethyl-1-oxido-6-phenyl-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-17-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2R,4R,5R)-4-(3-chlorophenyl)-5-methoxy-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-18-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(2,3-difluorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 862189-19-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(2-bromophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-20-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(3,4-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-21-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-[3,5-bis(trifluoromethyl)phenyl]-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-22-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-[3-(trifluoromethyl)phenyl]-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-23-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(2,4-dichlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862189-24-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[(2S,4R)-4-(5-bromo-3-pyridinyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

10/602,142


Absolute stereochemistry.



RN 862189-25-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(3-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-38-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3-O-acetyl-2-C-methyl-5-O-[(2S,4R)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862189-45-5 CAPLUS

CN L-Valine, 3'-ester with 7-[5-O-[(2S,4R)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine

McIntosh

10/602,142


d]pyrimidin-4-amine, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 862189-44-4

CMF C26 H33 Cl N5 O8 P


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 862189-46-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-[2-oxido-6-(3-pyridinyl)-1,4,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 862189-51-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-C-methyl-5-O-[(2R,4S)-2-oxido-4-(2-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862190-46-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl-β-D-ribofuranosyl]-, mono(trifluoromethanesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 862188-65-6

CMF C21 H24 Cl N4 O7 P

Absolute stereochemistry.

McIntosh


10/602,142



CM 2

CRN 1493-13-6


CMF C H F3 O3 S



RN 862300-23-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-
[(2 α ,4 β ,6 β)-2-oxido-4,6-diphenyl-1,3,2-dioxaphosphorinan-2-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 443642-29-3 443642-33-9 443642-38-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 2'-C-Me nucleoside derivs. and their uses for the treatment of hepatitis C viral infection)


RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

McIntosh


10/602,142



RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-38-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 862189-39-7P 862189-42-2P 862189-43-3P
862189-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 2'-C-Me nucleoside derivs. and their uses for the treatment
of hepatitis C viral infection)

RN 862189-39-7 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3-O-acetyl-5-O-[(2S,4R)-4-(3-

McIntosh

10/602,142

chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862189-42-2 CAPLUS

CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, 3'-ester with 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862189-43-3 CAPLUS

CN L-Valine, 3'-ester with 7-[5-O-[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 862189-50-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-azido-7-(2-C-methyl-β-D-ribofuranosyl) -
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:474924 CAPLUS

DN 143:7941

TI Preparation of nucleoside derivatives for treating Hepatitis C
virus infection

IN Roberts, Christopher D.; Keicher, Jesse; Dyatkina, Natalia B.

PA USA

SO U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 676,956.
CODEN: USXXCO


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005119200	A1	20050502	US 2004-821638	20040408
	US 2004147464	A1	20040729	US 2003-676956	20030930
PRAI	US 2002-415222P	P	20020930		
	US 2003-443169P	P	20030129		
	US 2003-676956	A2	20030930		
OS	CASREACT 143:7941; MARPAT 143:7941				
GI					

McIntosh



AB Disclosed are nucleosides I, wherein W-W2 are independently hydrogen and a pharmaceutically acceptable prodrug; R is hydrogen, alkyl; R1 is hydrogen, alkyl, alkenyl, alkenyl, alkynyl; Y is a bond, CH₂, O; Y' is hydrogen, halo, hydroxyl, thio-alkyl, amino; Z is acyl, cyano, carboxyl, carboxyl ester, amide, halo, B(OH)₂, imine, nitro, alkenyl, acetylenyl and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus. Thus, nucleoside II was prepared and used for the treatment of Hepatitis C virus infection. In general, compds. of this invention will be administered as pharmaceutical compns. by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., i.m., i.v. or s.c.) administration. The preferred manner of administration is oral using a convenient daily dosage regimen that can be adjusted according to the degree of affliction. Compns. can take the form of tablets, pills, capsules, semi-solids, powders, sustained release formulations, solns., suspensions, elixirs, aerosols, or any other appropriate compns. Another preferred manner for administering compds. of this invention is inhalation. This is an effective method for delivering a therapeutic agent directly to the respiratory tract, in particular for the treatment of diseases such as asthma and similar or related respiratory tract disorders.

IT 677298-90-7P 677299-07-9P 677299-11-5P
 852235-63-3P 852235-64-4P 852235-65-5P
 852235-66-6P 852235-67-7P 852235-68-8P
 852235-69-9P 852235-70-2P 852235-71-3P
 852235-72-4P 852235-73-5P 852235-74-6P
 852235-75-7P 852235-76-8P 852235-77-9P
 852235-78-0P 852235-79-1P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of nucleoside derivs. for treating Hepatitis C virus infection)

RN 677298-90-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 677299-07-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-ethynyl-1,7-dihydro-7-(2-C-methyl-beta-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677299-11-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-ethenyl-1,7-dihydro-7-(2-C-methyl-beta-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852235-63-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl-beta-D-ribofuranosyl)-5-(phenylethynyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 852235-64-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)-5-(2-pyridinylethynyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852235-65-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-[(4-fluorophenyl)ethynyl]-1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 852235-66-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-5-[(4-methylphenyl)ethynyl]-7-(2-C-methyl-beta-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852235-67-7 CAPLUS

CN 2-Propynoic acid, 3-[4-(hydroxyamino)-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 852235-68-8 CAPLUS

CN 2-Propynoic acid, 3-[4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852235-69-9 CAPLUS

CN 2-Propynamide, 3-[4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852235-70-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]-, oxime (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 852235-71-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852235-72-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 852235-73-5 CAPLUS


CN Boronic acid, [4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)-7H-

McIntosh

10/602,142

pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852235-74-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-(2,2-difluoroethenyl)-1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852235-75-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-5-[(1Z)-2-methoxyethenyl]-7-(2-C-methyl-β-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




McIntosh

10/602,142

RN 852235-76-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-5-nitro-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852235-77-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-ethynyl-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-, O-methyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852235-78-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-5-nitro-, O-methyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 852235-79-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-(methoxyamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 677299-09-1P 677299-10-4P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nucleoside derivs. for treating Hepatitis C virus infection)

RN 677299-09-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro-5-[(trimethylsilyl)ethynyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 677299-10-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/602,142



L6 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:431387 CAPLUS
DN 142:447384
TI Preparation of amino acid-containing nucleosides for treating
viral infections
IN Keicher, Jesse D.; Roberts, Christopher D.; Dyatkina, Natalia B.
PA Genelabs Technologies, Inc., USA
SO U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 861,090.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005107312	A1	20050519	US 2004-970321	20041020
	US 2006079468	A1	20060413	US 2004-861090	20040604
PRAI	US 2003-515153P	P	20031027		
	US 2004-861090	A2	20040604		
	US 2004-602815P	P	20040818		
OS	MARPAT 142:447384				
GI					



AB Disclosed are nucleosides I, wherein Y is bond, $-\text{CH}_2-$ $-\text{O}-$; W-W2 are independently H, and a pharmaceutically acceptable prodrug; compns. and

McIntosh

methods for treating viral infections caused by a Flaviviridae family virus, such as Hepatitis C virus. Thus, I (Y = O, W-W2 = H) was prepared and tested as antiviral agent against Hepatitis C virus (IC50 vales range from 0.09 to > 20 μ M).

IT 851387-62-7P 851387-64-9P 851387-65-0P

851387-66-1P 851387-67-2P 851387-68-3P

851387-69-4P 851387-70-7P 851387-71-8P

851387-72-9P 851387-73-0P 851387-74-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid-containing nucleosides for treating viral infections)

RN 851387-62-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-64-9 CAPLUS

CN L-Valine, 3'-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-65-0 CAPLUS

CN L-Alanine, 3'-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 851387-66-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3-O-(2,2-dimethyl-1-oxopropyl)-2-C-methyl- β -D-ribofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-67-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-68-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 851387-69-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)-5-(1-propynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-70-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(1-butynyl)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-71-8 CAPLUS

CN 2-Propyn-1-ol, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 851387-72-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3-amino-1-propynyl)-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-73-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-[5-O-(hydroxy(phosphonooxy)phosphinyl)-2-C-methyl- β -D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-74-1 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, (P->5')-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.

McIntosh



IT 847551-25-1P 847551-48-8P 847551-49-9P
 850338-22-6P 851387-63-8P 851387-75-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of amino acid-containing nucleosides for treating viral
 infections)
 RN 847551-25-1 CAPLUS
 CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-
 methyl-β-D-ribofuranosyl]-4-chloro-5-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-48-8 CAPLUS
 CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-iodo-7-(2-C-methyl-β-D-
 ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 847551-49-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-iodo-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-22-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-63-8 CAPLUS

CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, 5'-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 851387-75-2 CAPLUS

CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, 3'-ester with
5-ethynyl-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-
4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:409541 CAPLUS

DN 142:463969

TI Preparation of amino acid-containing nucleosides for treating
viral infections

IN Keicher, Jesse D.; Roberts, Christopher Don; Dyatkina, Natalia B.

PA Genelabs Technologies, Inc., USA

SO PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042556	A1	20050512	WO 2004-US34955	20041020
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

McIntosh

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

	US 2006079468	A1	20060413	US 2004-861090	20040604
	AU 2004285923	A1	20050512	AU 2004-285923	20041020
	CA 2542776	AA	20050512	CA 2004-2542776	20041020
PRAI	US 2003-515153P	P	20031027		
	US 2004-861090	A	20040604		
	US 2004-602815P	P	20040818		
	WO 2004-US34955	W	20041020		
OS	MARPAT 142:463969				
GI					



AB Disclosed are nucleosides I, wherein Y is bond, -CH₂- -O-; W-W₂ are independently H, and a pharmaceutically acceptable prodrug; compns. and methods for treating viral infections caused by a Flaviviridae family virus, such as Hepatitis C virus. Thus, I (Y = O, W-W₂ = H) was prepared and tested as antiviral agent against Hepatitis C virus (IC₅₀ vales range from 0.09 to > 20 μM).

IT 851387-62-7P 851387-64-9P 851387-65-0P
 851387-66-1P 851387-67-2P 851387-68-3P
 851387-69-4P 851387-70-7P 851387-71-8P
 851387-72-9P 851387-73-0P 851387-74-1P
 851387-76-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino acid-containing nucleosides for treating viral infections)

RN 851387-62-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 851387-64-9 CAPLUS

CN L-Valine, 3'-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-65-0 CAPLUS

CN L-Alanine, 3'-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-66-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3-O-(2,2-dimethyl-1-oxopropyl)-2-C-methyl- β -D-ribofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 851387-67-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-[5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-68-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-(2-C-methyl-5-O-phosphono-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-69-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-beta-D-ribofuranosyl)-5-(1-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 851387-70-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(1-butynyl)-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-71-8 CAPLUS

CN 2-Propyn-1-ol, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-72-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3-amino-1-propynyl)-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 851387-73-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-ethynyl-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851387-74-1 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, (P->5')-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-76-3 CAPLUS

CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)


Absolute stereochemistry.

McIntosh



IT 847551-25-1P 847551-48-8P 847551-49-9P
 850338-22-6P 851387-63-8P 851387-75-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of amino acid-containing nucleosides for treating viral
 infections)
 RN 847551-25-1 CAPLUS
 CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-
 methyl-β-D-ribofuranosyl]-4-chloro-5-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-48-8 CAPLUS
 CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-iodo-7-(2-C-methyl-β-D-
 ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 847551-49-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-iodo-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-22-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 851387-63-8 CAPLUS

CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, 5'-ester with 5-ethynyl-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 851387-75-2 CAPLUS

CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, 3'-ester with
5-ethynyl-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-
4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:369125 CAPLUS

DN 142:411590

TI Preparation of nucleosides for treating viral infections caused
by a Flaviviridae family virus

IN Roberts, Christopher D.; Keicher, Jesse D.

PA Genelabs Technologies, Inc., USA

SO U.S. Pat. Appl. Publ., 37 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005090463	A1	20050428	US 2004-861311	20040604
	CA 2543116	AA	20050519	CA 2004-2543116	20041020
	WO 2005044835	A1	20050519	WO 2004-US34756	20041020
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				


McIntosh

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005215510 A1 20050929 US 2004-970641 20041020
 AU 2004295291 A1 20050616 AU 2004-295291 20041021
 CA 2543090 AA 20050616 CA 2004-2543090 20041021
 WO 2005054268 A1 20050616 WO 2004-US35271 20041021

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005215511 A1 20050929 US 2004-971477 20041021
 PRAI US 2003-515153P P 20031027
 US 2004-861090 A 20040604
 US 2004-861219 A 20040604
 US 2004-861311 A 20040604
 US 2004-602815P P 20040818
 WO 2004-US34756 W 20041020
 WO 2004-US35271 W 20041021
 OS MARPAT 142:411590
 GI



AB Disclosed are nucleosides I, wherein selected from the group consisting of silyl, amide, alkoxyalkyl, heteroaryl, substituted Ph, alkenyl, alkynyl, alkoxy, acyl, acylamino, acyloxy, aminoacyl, amidino, amino, carboxyl, carboxyl ester, cyano, cycloalkyl, cyclo-alkoxy, guanidino, halo,

heteroaryl, hydrazino, hydroxyl, nitro, thiol, sulfonyl; and methods for treating viral infections caused by a Flaviviridae family virus, such as Hepatitis C virus. Thus, I (R = CONH2, Y = O, W-W2 = H) was prepared and tested as antiviral agent against Hepatitis C virus. Y is CH or O; each of W-W2 is independently hydrogen and a pharmaceutically acceptable prodrug; R is. Title nucleosides in combination with the administration of a therapeutically effective amount of one ore more agents active against HCV are reported.

IT 850338-22-6P 850338-24-8P 850338-25-9P
 850338-26-0P 850338-27-1P 850338-28-2P
 850338-29-3P 850338-30-6P 850338-31-7P
 850338-32-8P 850338-33-9P 850338-34-0P
 850338-35-1P 850338-36-2P 850338-37-3P
 850338-38-4P 850338-39-5P 850338-40-8P
 850338-41-9P 850338-42-0P 850338-43-1P
 850338-44-2P 850338-45-3P 850338-46-4P
 850338-47-5P 850338-48-6P 850338-49-7P
 850338-50-0P 850338-51-1P 850338-52-2P
 850338-53-3P 850338-54-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleosides for treating viral infections caused by flaviviridae family virus)

RN 850338-22-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-24-8 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 850338-25-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3,3-diethoxy-1-propynyl)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-26-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-5-(2-pyridinylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 850338-27-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-5-(4-pyridinylethynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-28-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-methoxyphenyl)ethynyl]-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-29-3 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-30-6 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, hydrazide (9CI). (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-31-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-32-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-5-(2-pyridiny lethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-5-(4-pyridinylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-34-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[(4-methoxyphenyl)ethynyl]-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-35-1 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-36-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3,3-diethoxy-1-propynyl)-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 850338-37-3 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-38-4 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-39-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny]l]-2-C-methyl- β -D-ribofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-40-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphinyloxy]-2-C-methyl-β-D-ribofuranosyl]-5-(2-pyridinylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-41-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphinyloxy]-2-C-methyl-β-D-ribofuranosyl]-5-(4-pyridinylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-42-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(hydroxy(phosphonooxy)phosphiny
1]-2-C-methyl-beta-D-ribofuranosyl]-5-[(4-methoxyphenyl)ethynyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 850338-43-1 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[5-O-[(hydroxy(phosphonooxy)phosphinyl)-2-C-
methyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 850338-44-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3,3-diethoxy-1-propynyl)-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-45-3 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850338-46-4 CAPLUS


CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, (9CI) (CA INDEX NAME)

McIntosh

10/602,142

1-hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-47-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-48-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-(2-pyridinylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 850338-49-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-(4-pyridinylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-50-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-[(4-methoxyphenyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 850338-51-1 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850338-52-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(3,3-diethoxy-1-propynyl)-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 850338-53-3 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850338-54-4 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 847551-25-1P 847551-48-8P 847551-49-9P
850338-23-7P

McIntosh


10/602,142

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of nucleosides for treating viral infections caused
by flaviviridae family virus)

RN 847551-25-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-
methyl-β-D-ribofuranosyl]-4-chloro-5-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-48-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-iodo-7-(2-C-methyl-β-D-
ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-49-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-iodo-7-(2-C-methyl-β-D-
ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 850338-23-7 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:216831 CAPLUS

DN 142:298286

TI Preparation of tricyclic nucleosides or nucleotides as antiviral and antitumor therapeutic agents

IN Cook, Phillip Dan; Ewing, Gregory; Jin, Yi; Lambert, John; Prhavic, Marija; Rajappan, Vasanthakumar; Rajwanshi, Vivek K.; Sakthivel, Kandasamy

PA Biota, Inc., USA

SO PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005021568	A2	20050310	WO 2004-US27819	20040827
	WO 2005021568	B1	20040609		
	WO 2005021568	A3	20050421		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				

McIntosh

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004269026	A1	20050310	AU 2004-269026	20040827
CA 2537114	AA	20050310	CA 2004-2537114	20040827
EP 1660511	A2	20060531	EP 2004-782317	20040827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
NO 2006000979	A	20060502	NO 2006-979	20060228
PRAI US 2003-498425P	P	20030827		
WO 2004-US27819	W	20040827		
OS MARPAT 142:298286				
GI				



AB Nucleosides and nucleotides containing a tricyclic base portion I, wherein A is O, S, CH₂, NH, CHF, CF₂; R₁, R₂, R₂', R₃, R₃', R₄ are independently H, F, Cl, iodo, Br, OH, SH, NH₂, NHOH, NHNH₂, N₃, COOH, CN, CONH₂, CSNH₂, COOR, R, OR, SR, SSR, NHR, NR₂; R₄' is L-R₅; L is O, S, NH, NR, CY₂S, CY₂NH, CY₂, CY₂CY₂, CY₂OCY₂, CY₂SCY₂, CY₂NHCY₂; Y is H, F, Cl, Br, alkyl, alkenyl, alkynyl, R₄' is OH, monophosphate, diphosphate, triphosphate; B is substituted tricyclic nucleobase derivs.; R is alkyl, alkenyl, alkynyl, aryl, acyl, aralkyl; thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer resp. Thus, nucleotide II was prepared and tested in vitro as polymerase inhibitor, antiviral, and antitumor therapeutic agent. Title compds. were typically cytotoxic in the range of 30 to > 100 μM. II showed inhibitory of NS5B in the range of 100 to >1000 nM. Selected examples displayed IC₅₀ values in the range of to 100 nM.

IT 847551-17-1P 847551-39-7P 847551-51-3P
 847551-53-5P 847551-55-7P 847551-56-8P
 847551-63-7P 847551-65-9P 847551-67-1P
 847551-68-2P 847551-75-1P 847551-76-2P
 847551-78-4P 847551-79-5P 847551-81-9P
 847551-83-1P 847551-84-2P 847551-85-3P
 847551-87-5P 847551-88-6P 847551-90-0P
 847551-91-1P 847551-93-3P 847551-94-4P

10/602,142

847551-95-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic nucleosides or nucleotides as antiviral and antitumor therapeutic agents)

RN 847551-17-1 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene, 3,7,8,9-tetrahydro-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-39-7 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3,8,9-tetrahydro-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-51-3 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-2-(2-C-methyl- β -D-ribofuranosyl)-9-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 847551-53-5 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-2-(2-C-methyl- β -D-ribofuranosyl)-8-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-55-7 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-9-methoxy-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 847551-56-8 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 8-bromo-2,3,8,9-tetrahydro-9-methoxy-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-63-7 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 4-fluoro-2,3-dihydro-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-65-9 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulen-7-amine, 2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 847551-67-1 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene, 7-methoxy-2-(2,3,5-tri-O-acetyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-68-2 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene, 7-methoxy-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 847551-75-1 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-2-(2-C-methyl- β -D-ribofuranosyl)-4-(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-76-2 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 4-chloro-2,3,8,9-tetrahydro-9-(methylthio)-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-78-4 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-4-(methylamino)-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 847551-79-5 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-4-methoxy-2-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-81-9 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulene-7-thione, 2,3-dihydro-2-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 847551-83-1 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene, 3,7-dihydro-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-84-2 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene, 3,7,8,9-tetrahydro-9-methoxy-2-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-85-3 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-2-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 847551-87-5 CAPLUS

CN 7-Oxa-2,3,5,6-tetraazabenz[cd]azulene, 2,3,8,9-tetrahydro-2-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-88-6 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene, 3,7,8,9-tetrahydro-2-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 847551-90-0 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 4-amino-2,3-dihydro-2-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-91-1 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3,8,9-tetrahydro-2-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-93-3 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 4-fluoro-2,3-dihydro-2-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 847551-94-4 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-2-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-9-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-95-5 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-2-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]-9-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 847551-69-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic nucleosides or nucleotides as antiviral and antitumor therapeutic agents)

RN 847551-69-3 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene-4,7(5H,6H)-dione, 2-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 847551-05-7P 847551-06-8P 847551-07-9P

847551-08-0P 847551-09-1P 847551-13-7P

847551-14-8P 847551-15-9P 847551-16-0P

847551-25-1P 847551-26-2P 847551-27-3P

847551-28-4P 847551-48-8P 847551-49-9P

847551-50-2P 847551-52-4P 847551-54-6P

847551-57-9P 847551-58-0P 847551-59-1P

847551-60-4P 847551-61-5P 847551-62-6P

847551-64-8P 847551-66-0P 847551-70-6P

847551-71-7P 847551-72-8P 847551-73-9P

847551-74-0P 847551-77-3P 847551-80-8P

847551-82-0P 847551-96-6P 847551-97-7P

847655-24-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of tricyclic nucleosides or nucleotides as antiviral and antitumor therapeutic agents)

10/602,142

RN 847551-05-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro-5-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-06-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-ethanol, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-07-9 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl]ethoxy]- (9CI) (CA INDEX NAME)

McIntosh

Absolute stereochemistry.


The chemical structure shows a benzimidazole ring system. The benzimidazole has a carbonyl group at the 2-position and an N-alkoxy group at the 1-position. The alkoxy chain consists of a methylene group followed by a CH₂ group attached to the 4-position of an indole ring. The indole ring is fused to a pyrimidine ring, which has a chlorine atom at the 6-position. The nitrogen at the 3-position of the indole ring is attached to a ribose sugar. The ribose sugar has a methyl group at the 2-position (wedge), a hydroxyl group at the 3-position (dash), and an O-alkoxy group at the 4-position. The alkoxy chain from the ribose is connected to a 3,5-dichlorobenzyl group. A vertical line with a chlorine atom at the bottom is also present.



CN 7-Oxa-2,3,5,6-tetraazabenz[cd]azulene, 2-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-2,3,8,9-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 847551-09-1 CAPLUS

CN 7-Oxa-2,3,5,6-tetraazabenz[cd]azulene, 2,3,8,9-tetrahydro-2-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-13-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 847551-14-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-propanol, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 847551-15-9 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 847551-16-0 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene, 2-[3,5-bis-O-[(3,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-3,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-25-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 847551-26-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-5-iodo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 847551-27-3 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 847551-28-4 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-2-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-48-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-iodo-7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 847551-49-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-iodo-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-50-2 CAPLUS

CN 2-Butenoic acid, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, methyl ester, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 847551-52-4 CAPLUS


CN 2-Propenoic acid, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh

10/602,142


Double bond geometry unknown.



RN 847551-54-6 CAPLUS

CN 2-Propenoic acid, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-3-methoxy-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 847551-57-9 CAPLUS

CN Propanamide, N-[7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-58-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 4-chloro-5-iodo-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-59-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 5-iodo-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-60-4 CAPLUS

CN 2-Propenoic acid, 3-[2,4-diamino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, methyl ester, (2E)-(9CI) (CA INDEX NAME)

McIntosh


10/602,142

Absolute stereochemistry.
Double bond geometry as shown.



RN 847551-61-5 CAPLUS
CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 4-amino-2,3-dihydro-2-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-62-6 CAPLUS
CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 4-amino-2-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-C-methyl-beta-D-ribofuranosyl]-2,3-dihydro-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 847551-64-8 CAPLUS

CN 2-Propenenitrile, 3-[4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 847551-66-0 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2,3-dihydro-2-(2,3,5-tri-O-acetyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 847551-70-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-2,4-dichloro-5-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-71-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-2-chloro-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847551-72-8 CAPLUS


CN 2-Propenoic acid, 3-[4-amino-7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-2-chloro-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

McIntosh


10/602,142



RN 847551-73-9 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 2-[3,5-bis-O-[(3,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-74-0 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 4-chloro-2,3-dihydro-2-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 847551-77-3 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulen-7-one, 4-chloro-2-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-C-methyl- β -D-ribofuranosyl]-2,3-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-80-8 CAPLUS

CN 7H-2,3,5,6-Tetraazabenz[cd]azulene-7-thione, 2,3-dihydro-2-(2,3,5-tri-O-acetyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 847551-82-0 CAPLUS

CN 2H-2,3,5,6-Tetraazabenz[cd]azulene, 2-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-3,7-dihydro-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847551-96-6 CAPLUS

CN 7-Oxa-2,3,5,6-tetraazabenz[cd]azulene, 6-acetyl-2-(2,3-di-O-acetyl-2-C-methyl- β -D-ribofuranosyl)-2,6,8,9-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847551-97-7 CAPLUS

CN 2-Propenoic acid, 3-[4-amino-7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

McIntosh

10/602,142



RN 847655-24-7 CAPLUS
CN Borate(4-), trihydro[2,3,8,9-tetrahydro-2-[5-O-
[[[(difluorophosphonomethyl)hydroxyphosphinyl]oxy]hydroxyphosphino-
κP]-2-C-methyl-β-D-ribofuranosyl]-7-oxa-2,3,5,6-
tetraazabenz[cd]azulenato(4-)]-, tetrahydrogen, (T-4)- (9CI) (CA INDEX
NAME)



● 4 H⁺

L6 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:216597 CAPLUS
DN 142:291323
TI Compositions and methods for the treatment of severe acute respiratory
syndrome (SARS)
IN Hardee, Greg; Dellamary, Luis
PA Isis Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 217 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

McIntosh

10/602,142

PI WO 2005020885 A2 20050310 WO 2004-US16196 20040521
WO 2005020885 A3 20050804

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRAI US 2003-472774P P 20030521

AB The invention provides compns. and methods for treating a coronavirus infection, especially a SARS CoV infection. The compns. comprise an antiviral nucleoside or mimetic thereof, or an antiviral antisense agent, in a form suitable for pulmonary or nasal delivery. The methods comprise administration to a patient in need thereof the effective amount of an antiviral composition by pulmonary or nasal instillation.

IT 139209-26-0 141232-24-8 443642-28-2
443642-29-3 443642-33-9 443642-34-0
443642-37-3 443642-38-4 443642-40-8
443642-41-9 443642-42-0 443642-43-1
443642-44-2 443642-45-3 443642-46-4
443642-47-5 443642-48-6 443642-49-7
443642-53-3 443642-56-6 443642-60-2
443642-63-5 443642-66-8 443642-67-9
443642-80-6 443642-83-9 443642-96-4
443642-98-6 443643-09-2 443643-11-6
443643-17-2 443643-26-3 443643-28-5
443643-29-6 443643-31-0 443643-37-6
582313-35-7 582313-49-3 582313-51-7
790240-68-5 847651-47-2 847651-50-7
847651-53-0 847651-63-2 847651-64-3
847651-65-4 847651-75-6 847651-78-9
847651-85-8 847651-88-1 847651-92-7
847652-03-3 847652-12-4 847655-34-9
847655-35-0 847655-36-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(compns. and methods for treatment of severe acute respiratory syndrome)

RN 139209-26-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 141232-24-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-28-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

McIntosh


10/602,142



RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-34-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-37-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-ethyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-38-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-40-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-41-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-cyclopropyl-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-42-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-43-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny]l]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-44-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphiny]oxy]phosphiny]l]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-45-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-46-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-chloro-7-(2-C-methyl-β-D-ribofuranosyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-47-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-bromo-7-(2-C-methyl-β-D-ribofuranosyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-48-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-49-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-(2-C-methyl-2-O-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-53-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-methyl-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-56-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxylic acid, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-60-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(hydroxymethyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-63-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(fluoromethyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-66-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-2-C-methyl-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-67-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-2-C-methyl-β-D-threo-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-80-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-3-fluoro-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-83-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-2-O-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-96-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-98-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443643-09-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(fluoromethyl)-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-11-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443643-17-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-fluoro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RN 443643-26-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-28-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-ethyl-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443643-29-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-2-O-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

10/602,142


Absolute stereochemistry.



RN 443643-31-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-37-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3-deoxy-3-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 582313-35-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-3-O-(1-oxooctyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 582313-49-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-C-methyl-3-O-(1-oxooctyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 582313-51-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-3,5-bis-O-(1-oxooctyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 790240-68-5 CAPLUS

McIntosh

10/602,142

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-chloro-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847651-47-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-3-O-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847651-50-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-methoxy-5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847651-53-0 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-3-O-[7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- β -D-

McIntosh

10/602,142

ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847651-63-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-fluoro- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847651-64-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-fluoro-5-O-(4-methylbenzoyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 847651-65-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -L-ribofuranosyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847651-75-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl- β -D-arabinofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847651-78-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbothioamide, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847651-85-8 CAPLUS

McIntosh

10/602,142

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-arabinofuranosyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 847651-88-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 2,4-difluoro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847651-92-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(aminomethyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 847652-03-3 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-[2-C-methyl-5-O-phosphono-

McIntosh

10/602,142

β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847652-12-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-3,3-difluoro-2-C-methyl- β -D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847655-34-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(5-O-acetyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847655-35-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3,5-di-O-acetyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 847655-36-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-ol, 2-amino-7-(2-C-methyl-β-D-ribofuranosyl)-, 4-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:74691 CAPLUS

DN 142:336574

TI Synthesis of 2'-β-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors

AU Ding, Yili; An, Haoyun; Hong, Zhi; Girardet, Jean-Luc

CS Valeant Pharmaceuticals, Inc., Costa Mesa, CA, 92626, USA

SO Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 725-727

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 142:336574

AB Coupling reaction of 2-β-C-methyl-1,2,3,4-tetra-O-benzoyl-D-ribofuranose with 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine, followed by debromination and debenzoylation, gave the 2'-β-C-Me toyocamycin in high yield. Based on this result, a series of 2'-β-C-methyl-4-substituted toyocamycin and sangivamycin analogs were synthesized for biol. screening as potential inhibitors of HCV RNA replication.

IT 141232-24-8P 565455-19-8P 677298-90-7P

677298-94-1P 848645-25-0P 848645-29-4P

848645-30-7P

RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic

McIntosh

10/602,142


preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of 2'- β -C-Me toyocamycin and sangivamycin analogs via coupling reaction as potential HCV inhibitors)

RN 141232-24-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 565455-19-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-(methyamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 677298-90-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-(hydroxyamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 677298-94-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-(methoxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848645-25-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 848645-29-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-(dimethylamino)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 848645-30-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-methoxy-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 139209-26-0P 565455-20-1P 565455-21-2P

565455-24-5P 565455-25-6P 677298-95-2P

848645-26-1P 848645-27-2P 848645-28-3P

848645-31-8P 848645-32-9P 848645-33-0P

848645-34-1P 848645-35-2P 848645-36-3P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);


BIOL (Biological study); PREP (Preparation)

(synthesis of 2'-beta-C-Me toyocamycin and sangivamycin analogs via coupling reaction as potential HCV inhibitors)

RN 139209-26-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 565455-20-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-(methylamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 565455-21-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, 4-(dimethylamino)-N-hydroxy-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 565455-24-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, 4,7-dihydro-N-hydroxy-7-(2-C-methyl- β -D-ribofuranosyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 565455-25-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, 4-amino-N-hydroxy-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677298-95-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-(methoxyamino)-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 848645-26-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4,7-dihydro-7-(2-C-methyl-beta-D-ribofuranosyl)-4-oxo- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 848645-27-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboximide, 4,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-4-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848645-28-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximide, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 848645-31-8 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-(methylamino)-7-(2-C-methyl-

McIntosh

10/602,142

β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848645-32-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-(dimethylamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848645-33-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-(methoxyamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 848645-34-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-methoxy-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848645-35-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, N-methyl-4-(methylamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 848645-36-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidic acid, 4-(hydroxyamino)-7-(2-C-methyl- β -D-ribofuranosyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

10/602,142

IT 565455-18-7P 729595-78-2P 729595-79-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of 2'- β -C-Me toyocamycin and sangivamycin analogs via coupling reaction as potential HCV inhibitors)

RN 565455-18-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-chloro-7-(2,3,5-tri-O-acetyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 729595-78-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2,3,5-tri-O-benzoyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 729595-79-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-6-bromo-7-(2,3,5-tri-O-benzoyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1127101 CAPLUS
DN 142:49201
TI Inhibiting Coronaviridae viral replication and treating
Coronaviridae viral infection with nucleoside compounds
IN Olsen, David B.; Tomassini, Joanne E.; Mao, Shi-Shan; Carroll, Steven S.
PA USA
SO U.S. Pat. Appl. Publ., 19 pp., which
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004259934	A1	2004/1223	US 2004-832945	20040427
PRAI	US 2003-467068P	P	20030501		
	US 2003-470658P	P	20030515		
OS	MARPAT 142:49201				
AB	Infection by a Coronaviridae virus (e.g. a coronavirus) and/or illness due to a Coronaviridae virus are treated or protected against by administration of a therapeutically or prophylactically effective amount of certain nucleoside compds. and derivs. thereof, either alone or in a composition comprising the nucleoside compound or its derivative and a pharmaceutically acceptable carrier. In addition, replication of a Coronaviridae virus is inhibited by administration of the nucleoside compds. and derivs. thereof, either alone or in pharmaceutical compns. The nucleosides are particularly suitable for use in treating or prophylaxis of an infection by the SARS virus and/or in treating or prophylaxis of SARS, and for use in inhibiting replication of the SARS virus. The nucleoside compds. and derivs. can optionally be administered in combination with other agents active against the Coronaviridae virus and/or an illness due to the virus. The nucleoside compds. are also for use in the manufacture of medicaments for the inhibition of Coronaviridae virus replication, for the treatment or prophylaxis of Coronaviridae virus infection, and/or for the treatment or prophylaxis of an illness due to a Coronaviridae virus (e.g., the SARS virus). In addition, the compds. are for use as medicaments for the inhibition of Coronaviridae virus replication, for the treatment or prophylaxis of Coronaviridae virus infection, and/or for the treatment or prophylaxis of an illness due to a Coronaviridae virus. Compds. of the invention include e.g. 4-Amino-7-(2-C-methyl-β-D-				

10/602,142


IT 443642-29-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleoside compds. for inhibition of Coronaviridae viral replication and treating Coronaviridae viral infection)
RN 443642-29-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 443642-44-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleoside compds. for inhibition of Coronaviridae viral replication and treating Coronaviridae viral infection)
RN 443642-44-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 443642-32-8P 443642-33-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(nucleoside compds. for inhibition of Coronaviridae viral replication and treating Coronaviridae viral infection)
RN 443642-32-8 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:848340 CAPLUS

DN 142:226

TI A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

AU Olsen, David B.; Eldrup, Anne B.; Bartholomew, Linda; Bhat, Balkrishen; Bosserman, Michele R.; Ceccacci, Alessandra; Colwell, Lawrence F.; Fay, John F.; Flores, Osvaldo A.; Getty, Krista L.; Grobler, Jay A.; LaFemina, Robert L.; Markel, Eric J.; Migliaccio, Giovanni; Prhavic, Marija; Stahlhut, Mark W.; Tomassini, Joanne E.; MacCoss, Malcolm; Hazuda, Daria J.; Carroll, Steven S.

CS Department of Biological Chemistry, Merck Research Laboratories, West Point, PA, USA

SO Antimicrobial Agents and Chemotherapy (2004), 48(10), 3944-3953
CODEN: AMACQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

McIntosh

LA English

AB Improved treatments for chronic hepatitis C virus (HCV) infection are needed due to the suboptimal response rates and deleterious side effects associated with current treatment options. The triphosphates of 2'-C-methyl-adenosine and 2'-C-methyl-guanosine were previously shown to be potent inhibitors of the HCV RNA-dependent RNA polymerase (RdRp) that is responsible for the replication of viral RNA in cells. Here we demonstrate that the inclusion of a 7-deaza modification in a series of purine nucleoside triphosphates results in an increase in inhibitory potency against the HCV RdRp and improved pharmacokinetic properties. Notably, incorporation of the 7-deaza modification into 2'-C-methyl-adenosine results in an inhibitor with a 20-fold-increased potency as the 5'-triphosphate in HCV RdRp assays while maintaining the inhibitory potency of the nucleoside in the bicistronic HCV replicon and with reduced cellular toxicity. In contrast, while 7-deaza-2'-C-methyl-GTP also displays enhanced inhibitory potency in enzyme assays, due to poor cellular penetration and/or metabolism, the nucleoside does not inhibit replication of a bicistronic HCV replicon in cell culture. 7-Deaza-2'-C-methyl-adenosine displays promising in vivo pharmacokinetics in three animal species, as well as an acute oral LD in excess of 2,000 mg/kg of body weight in mice. Taken together, these data demonstrate that 7-deaza-2'-C-methyl-adenosine is an attractive candidate for further investigation as a potential treatment for HCV infection.

IT 443642-44-2 443643-26-3


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(a 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties)

RN 443642-44-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-26-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:773084 CAPLUS
DN 141:388156
TI Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl
Ribonucleosides as Inhibitors of Hepatitis C Virus RNA
Replication
AU Eldrup, Anne B.; Prhavic, Marija; Brooks, Jennifer; Bhat, Balkrishen;
Prakash, Thazha P.; Song, Quanlai; Bera, Sanjib; Bhat, Neelima; Dande,
Prasad; Cook, P. Dan; Bennett, C. Frank; Carroll, Steven S.; Ball, Richard
G.; Bosserman, Michele; Burlein, Christine; Colwell, Lawrence F.; Fay,
John F.; Flores, Osvaldo A.; Getty, Krista; LaFemina, Robert L.; Leone,
Joseph; MacCoss, Malcolm; McMasters, Daniel R.; Tomassini, Joanne E.; Von
Langen, Derek; Wolanski, Bohdan; Olsen, David B.
CS Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA,
92008, USA
SO Journal of Medicinal Chemistry (2004), 47(21), 5284-5297
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:388156
AB Hepatitis C virus infection constitutes a significant health
problem in need of more effective therapies. The authors have recently
identified 2'-C-methyladenosine and 2'-C-methylguanosine as potent
nucleoside inhibitors of HCV RNA replication in vitro. However,
both of these compds. suffered from significant limitations.
2'-C-Methyladenosine was found to be susceptible to enzymic conversions by
adenosine deaminase and purine nucleoside phosphorylase, and it displayed
limited oral bioavailability in the rat. 2'-C-Methylguanosine, on the
other hand, was neither efficiently taken up in cells nor phosphorylated
well. As part of an attempt to address these limitations, the authors now
report upon the synthesis and evaluation of a series of
heterobase-modified 2'-C-Me ribonucleosides. The structure-activity
relationship within this series of nucleosides reveals
4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
and 4-amino-5-fluoro-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-
d]pyrimidine as potent and noncytotoxic inhibitors of HCV RNA
replication. Both 4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-
pyrrolo[2,3-d]pyrimidine and 4-amino-5-fluoro-7-(2-C-methyl-β-D-
ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine display improved enzymic
stability profiles as compared to that of 2'-C-methyladenosine.
Consistent with these observations, the most potent compound,
4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine ribonucleoside, is orally

bioavailable in the rat. Together, the potency of the 2'-C-methyl-4-amino-pyrrolo[2,3-d]pyrimidine ribonucleosides and their improved pharmacokinetic properties relative to that of 2'-C-methyladenosine suggests that this class of compds. may have clin. utility.


IT 443643-17-2P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-activity relationship of heterobase-modified 2'-C-Me ribonucleosides as inhibitors of hepatitis C virus RNA replication)

RN 443643-17-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-fluoro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 443642-96-4P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(structure-activity relationship of heterobase-modified 2'-C-Me ribonucleosides as inhibitors of hepatitis C virus RNA replication)

RN 443642-96-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 443642-29-3P 443642-38-4P 443642-46-4P
443642-47-5P 443642-53-3P 443642-56-6P

10/602,142

443642-97-5P 790240-68-5P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure-activity relationship of heterobase-modified 2'-C-Me ribonucleosides as inhibitors of hepatitis C virus RNA replication)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 443642-38-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-46-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-chloro-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-47-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-bromo-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-53-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-56-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxylic acid, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-97-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 2-fluoro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 790240-68-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-chloro-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 139209-26-0 141232-24-8

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-activity relationship of heterobase-modified 2'-C-Me ribonucleosides as inhibitors of hepatitis C virus RNA replication)

RN 139209-26-0 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-(2-C-methyl- β -D-

McIntosh

10/602,142

ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141232-24-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 443642-32-8P 443642-33-9P 443642-39-5P

443642-40-8P 443642-54-4P 443642-55-5P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(structure-activity relationship of heterobase-modified 2'-C-Me ribonucleosides as inhibitors of hepatitis C virus RNA replication)

RN 443642-32-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-39-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-40-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 4-chloro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-54-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443642-55-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:702027 CAPLUS

DN 141:207474

TI Process for preparing branched ribonucleosides from 1,2-anhydribofuranose intermediates useful in the treatment of HCV infection

IN Xu, Feng; Bio, Matthew M.; Cowden, Cameron J.; Savary, Kimberly A.; Williams, John M.; Yang, Chunhua; Waters, Majorie See

PA Merck & Co. Inc., USA

SO PCT Int. Appl., 22 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004072090	A1	20040826	WO 2004-US3469	20040206
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1594882	A1	20051116	EP 2004-709000	20040206
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	US 2003-446935P	P	20030212		
	WO 2004-US3469	W	20040206		
OS	MARPAT 141:207474				
GI					



AB A process is provided for the preparation of branched-chain ribonucleosides I, wherein wherein R1 is C1-6 alkyl and B is a purine or pyrimidine nucleobase selected from the group consisting of cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine; from the 1,2-anhydro derivs. II, wherein PG is a hydroxy protecting group via ring cleavage of the anhydro ring with nucleobases. Compds. I are potential inhibitors of HCV polymerase and useful in the treatment of HCV infection. Thus, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine was prepared from diol III via ring cleavage of II (R1 = Me, PG = 4-methoxybenzoyl) with 4-phthalimido-7H-pyrrolo[2,3-d]pyrimidine.

IT 443642-29-3P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for preparing branched ribonucleosides from 1,2-anhydroribofuranoses useful for treatment of HCV via ring cleavage with nucleobases)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



10/602,142


AN 2004:650363 CAPLUS
DN 141:332398
TI Practical Synthesis of a Potent Hepatitis C Virus RNA
Replication Inhibitor
AU Bio, Matthew M.; Xu, Feng; Waters, Marjorie; Williams, J. Michael; Savary,
Kimberly A.; Cowden, Cameron J.; Yang, Chunhua; Buck, Elizabeth; Song,
Zhiguo J.; Tschaen, David M.; Volante, R. P.; Reamer, Robert A.;
Grabowski, Edward J. J.
CS Process Research, Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Journal of Organic Chemistry (2004), 69(19), 6257-6266
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:332398
AB A practical, efficient synthesis of 4-amino-7-(2'-C-methyl- β -D-
ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine, a hepatitis C virus
RNA replication inhibitor, is described. Starting with inexpensive
diacetone glucose, the 12-step synthesis features a novel stereoselective
rearrangement to prepare the key crystalline furanose diol intermediate. This
is followed by a highly selective glycosidation to couple the C-2 branched
furanose epoxide with deazapurine.
IT 769951-27-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis of 4-amino-7-(2'-C-methyl- β -D-ribofuranosyl)-7H-
pyrrolo[2,3-d]pyrimidine via stereoselective rearrangement, epoxide
ring opening, and stereoselective glycosidation)
RN 769951-27-1 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-
, compd. with methylbenzene (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 443642-29-3

CMF C12 H16 N4 O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 108-88-3

CMF C7 H8

McIntosh




IT 443642-29-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of 4-amino-7-(2'-C-methyl- β -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine via stereoselective rearrangement, epoxide ring opening, and stereoselective glycosidation)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:566635 CAPLUS

DN 141:89323

TI Process for the production of 3'-nucleoside prodrugs

IN Storer, Richard; Moussa, Adel; Mathieu, Steven; Qu, Lin

PA Idenix Cayman Limited, Cayman I.

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058792	A1	20040715	WO 2003-US41603	20031223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2511616 AA 20040715 CA 2003-2511616 20031223				

10/602,142

AU 2003300434	A1	20040722	AU 2003-300434	20031223
US 2004181051	A1	20040916	US 2003-746395	20031223
EP 1575971	A1	20050921	EP 2003-814400	20031223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016868	A	20051025	BR 2003-16868	20031223
CN 1751058	A	20060322	CN 2003-80109820	20031223
JP 2006514038	T2	20060427	JP 2004-562599	20031223
NO 2005003557	A	20050908	NO 2005-3557	20050720
PRAI US 2002-436150P	P	20021223		
WO 2003-US41603	W	20031223		
OS CASREACT 141:89323; MARPAT 141:89323				
GI				



AB Provided is a single-step process for the regioselective 3'-acylation of a ribofuranosyl 2'- or 3'-branched nucleosides I, wherein B is nucleobase. These compds. are useful as antiviral agents, and in particular, can be used to treat Flaviviridae infections in a host in need thereof (no data). Thus, 9-(2'-C-methyl-3'-O-valinoyl- β -D-ribofuranosyl)-6-N-methyladenine dihydrochloride was prepared via regioselective esterification of 9-(2'-C-methyl- β -D-ribofuranosyl)-6-N-methyladenine with N-(tert-butoxycarbonyl)-L-valine.

IT 443642-29-3P 443642-38-4P 443642-41-9P
443642-45-3P 443642-86-2P 443642-96-4P
629670-25-3P 714249-85-1P 714249-86-2P
714249-87-3P 714249-88-4P 714249-89-5P
714249-90-8P 714249-91-9P 714249-94-2P
714250-08-5P 714250-09-6P 714250-10-9P
714250-11-0P 714250-12-1P 714250-13-2P
714250-14-3P 714250-15-4P 714250-16-5P
714250-17-6P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for production of nucleoside prodrugs via regioselective esterification)


RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

McIntosh


10/602,142



RN 443642-38-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-41-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-cyclopropyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-45-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-86-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-96-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 629670-25-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 714249-85-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-methyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714249-86-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2,4-diamino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714249-87-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 714249-88-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 5-ethyl-7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714249-89-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidine-4-thione, 1,7-dihydro-7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714249-90-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidine-4-thione, 2-amino-1,7-dihydro-7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 714249-91-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714249-94-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-ethyl-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714250-08-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-ethyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 714250-09-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714250-10-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(1-methylethyl)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714250-11-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-butyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 714250-12-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2-methylpropyl)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714250-13-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(1,1-dimethylethyl)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714250-14-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 714250-15-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-cyclopentyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714250-16-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(3-methylbutyl)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714250-17-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-(2,2-dimethylpropyl)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

McIntosh


Absolute stereochemistry.



L6 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:465503 CAPLUS
 DN 141:157373
 TI Synthesis of new 2'-β-C-methyl related triciribine analogues as anti-HCV agents
 AU Smith, Kenneth L.; Lai, Vicky C. H.; Prigaro, Brett J.; Ding, Yili; Gunic, Esmir; Girardet, Jean-Luc; Zhong, Weidong; Hong, Zhi; Lang, Stanley; An, Haoyun
 CS Valeant Pharmaceuticals International, Costa Mesa, CA, 92626, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3517-3520
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 141:157373
 AB Ten new β-D-ribofuranosyl and 2'-β-C-methyl-β-D-ribofuranosyl triciribine derivs. with various N4 and 6-N substituents on the tricyclic ring were synthesized from the corresponding toyocamycin and new 2'-β-C-Me toyocamycin derivs. The inhibitory studies of these compds. in the HCV replicon assay reveal that some of them possess interesting anti-HCV properties with low cytotoxicity.
 IT 566152-71-4P 566152-73-6P 729595-69-1P
 729595-70-4P 729595-71-5P 729595-72-6P
 729595-73-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and anti-HCV anal. of β-D-ribofuranosyl and 2'-β-C-methyl-β-D-ribofuranosyl triciribine derivs. with various N4 and 6-N substituents on the tricyclic ring)
 RN 566152-71-4 CAPLUS
 CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 566152-73-6 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylene-3-amine, 5-ethyl-1,5-dihydro-1-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 729595-69-1 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylene-3-amine, 1,5-dihydro-1-(2-C-methyl-beta-D-ribofuranosyl)-5-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 729595-70-4 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 5-butyl-1,5-dihydro-1-(2-C-methyl- β -D-ribofuranosyl) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 729595-71-5 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylene-5(1H)-ethanol, 3-amino-1-(2-C-methyl- β -D-ribofuranosyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 729595-72-6 CAPLUS

CN Acetamide, N-[1,5-dihydro-5-methyl-1-(2-C-methyl- β -D-ribofuranosyl) - 1,4,5,6,8-pentaazaacenaphthylen-3-yl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 729595-73-7 CAPLUS

CN Acetamide, N- [1,5-dihydro-5-(2-hydroxyethyl)-1-(2-C-methyl-β-D-ribofuranosyl)-1,4,5,6,8-pentaazaacenaphthylen-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 729595-78-2P 729595-79-3P 729595-80-6P

729595-81-7P 729595-82-8P 729595-83-9P

729595-84-0P 729595-85-1P 729595-86-2P

729595-87-3P 729595-88-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and anti-HCV anal. of β-D-ribofuranosyl and 2'-β-C-methyl-β-D-ribofuranosyl triciribine derivs. with various N4 and 6-N substituents on the tricyclic ring)


RN 729595-78-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 729595-79-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-6-bromo-7-(2,3,5-tri-O-benzoyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 729595-80-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4,7-dihydro-4-oxo-7-(2,3,5-tri-O-benzoyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 729595-81-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-chloro-7-(2,3,5-tri-O-benzoyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 729595-82-8 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 729595-83-9 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 5-ethyl-1,5-dihydro-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 729595-84-0 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-propyl-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 729595-85-1 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 5-butyl-1,5-dihydro-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 729595-86-2 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylene-5(1H)-ethanol, 3-amino-1-(2,3,5-tri-O-benzoyl-2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 729595-87-3 CAPLUS

CN Acetamide, N-[1,5-dihydro-5-methyl-1-(2,3,5-tri-O-benzoyl-2-C-methyl- β -D-ribofuranosyl)-1,4,5,6,8-pentaazaacenaphthylen-3-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

McIntosh



RN 729595-88-4 CAPLUS
 CN Acetamide, N- [5- [2- (acetyloxy)ethyl] -1,5-dihydro-1- (2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl) -1,4,5,6,8-pentaazaacenaphthylen-3-yl] -
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:290484 CAPLUS
 DN 140:327061
 TI Nucleoside derivatives for treating hepatitis C virus infection
 IN Roberts, Christopher Don; Dyatkina, Natalia B.
 PA Genelabs Technologies, Inc., USA
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028481	A2	20040408	WO 2003-US31433	20030930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BE, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499253	AA	20040408	CA 2003-2499253	20030930
	AU 2003279797	A1	20040419	AU 2003-279797	20030930
	EP 1572097	A2	20050914	EP 2003-773127	20030930
	EP 1572097	A3	20051207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505537	T2	20060216	JP 2004-540353	20030930
	NO 2005001969	A	20050524	NO 2005-1969	20050422
PRAI	US 2002-415222P	P	20020930		
	US 2003-443169P	P	20030129		
	WO 2003-US31433	W	20030930		
OS	MARPAT 140:327061				
AB	Nucleoside compns. and methods for treating hepatitis C virus infections. Thus, 9-(2'-C-methyl-β-D-ribofuranosyl)-6-methoxyaminopurine was prepared by the reaction of 6-chloro-9-(2'-C-methyl-β-D-ribofuranosyl)purine and methoxylamine. This compound exhibited anti-hepatitis C activity by inhibiting HCV polymerase.				
IT	565455-26-7P 677298-71-4P 677298-75-8P 677298-84-9P 677298-85-0P 677298-86-1P 677298-88-3P 677298-90-7P 677298-92-9P 677298-93-0P 677298-94-1P 677298-95-2P 677299-07-9P 677299-11-5P 677299-12-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (nucleoside derivs. for treating hepatitis C virus infection)				
RN	565455-26-7 CAPLUS				
CN	7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-(hydroxyamino)-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/602,142

RN 677298-71-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677298-75-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-, O-methyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677298-84-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-chloro-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 677298-85-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-bromo-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677298-86-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677298-88-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-ethyl-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 677298-90-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-(hydroxyamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677298-92-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-bromo-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-, O-methyloxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677298-93-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)-, O-methyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 677298-94-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-(methoxyamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677298-95-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-(methoxyamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677299-07-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-ethynyl-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 677299-11-5 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 5-ethenyl-1,7-dihydro-7-(2-C-methyl-
β-D-ribofuranosyl)-, oxime (9CI) (CA INDEX NAME)

RN	677299-12-6	CAPLUS
CN	4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)-5-(5-oxazolyl)-, oxime (9CI) (CA INDEX NAME)	

Chemical structure of a nucleoside derivative. The structure consists of a purine-like base linked to a ribose sugar. The base has a hydroxyl group at the 6-position and a furan ring at the 2-position. The base is linked via its nitrogen at the 9-position to the 1-position of the ribose sugar. The ribose sugar has a methyl group at the 2-position and hydroxyl groups at the 3 and 4 positions. Stereochemistry is indicated with wedges and dashes.


```

IT      443642-33-9
        RL: RCT (Reactant); RACT (Reactant or reagent)
          (nucleoside derivs. for treating hepatitis C virus infection)
RN      443642-33-9  CAPLUS
CN      7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-β-D-
        ribofuranosyl)- (9CI)  (CA INDEX NAME)

```

McIntosh

10/602,142




IT 677299-09-1P 677299-10-4P 677299-13-7P
677299-14-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(nucleoside derivs. for treating hepatitis C virus infection)

RN 677299-09-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-[(trimethylsilyl)ethynyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 677299-10-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-β-D-ribofuranosyl)-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 677299-13-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 677299-14-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)-5-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:80452 CAPLUS

DN 140:122759

TI Thionucleoside derivatives as inhibitors of RNA-dependent RNA

McIntosh

viral polymerase

IN Olsen, David B.; Bhat, Balkrishen; Cook, Phillip Dan

PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009020	A2	20040129	WO 2003-US22556	20030718
	WO 2004009020	A3	20050224		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003256619	A1	20040209	AU 2003-256619	20030718
	US 2006122154	A1	20060608	US 2005-520925	20050926
PRAI	US 2002-398237P	P	20020724		
	WO 2003-US22556	W	20030718		
OS	MARPAT 140:122759				
AB	The present invention provides thionucleoside compds. and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such thionucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the thionucleoside compds. of the present invention.				
IT	651035-11-9P 651035-54-0P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of thionucleoside derivs. as inhibitors of RNA-dependent RNA viral polymerase)				
RN	651035-11-9 CAPLUS				
CN	7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-4-thio-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/602,142



RN 651035-54-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl-4-thio-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 651035-07-3P 651035-49-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thionucleoside derivs. as inhibitors of RNA-dependent RNA viral polymerase)

RN 651035-07-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-4-thio-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651035-49-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 4-chloro-7-(2-C-methyl-4-thio-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


McIntosh

Absolute stereochemistry.



L6 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:60522 CAPLUS
 DN 140:94238
 TI Preparation of nucleoside derivatives as antiviral agents and
 inhibitors of RNA-dependent RNA viral polymerase
 IN Bhat, Balkrishen; Carroll, Steven S.; Eldrup, Anne B.; Maccoss, Malcolm;
 Olsen, David B.; Prakash, Thazha P.
 PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004007512	A2	20040122	WO 2003-US21589	20030711
WO 2004007512	A3	20040408		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2490666	AA	20040122	CA 2003-2490666	20030711
AU 2003269902	A1	20040202	AU 2003-269902	20030711
EP 1556399	A2	20050727	EP 2003-751791	20030711
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005533108	T2	20051104	JP 2004-521624	20030711
PRAI US 2002-396252P	P	20020716		
WO 2003-US21589	W	20030711		
OS MARPAT 140:94238				
GI				



I

AB The present invention provides nucleoside I, wherein wherein R1 is F, alkyl, wherein alkyl is unsubstituted or substituted with hydroxy, amino, alkoxy, alkylthio; R2 is amino, F, OH, alkylcarbonyloxy, SH, alkoxy; R3 and R4 are each independently H, alkylcarbonyl, alkenylcarbonyl, alkyloxycarbonyl, cycloalkylcarbonyl, cycloalkyloxycarbonyl, CH₂O(C=O)-alkyl, acyl, with the proviso that at least one of R3 and R4 is not hydrogen; R5 and R6 are each independently hydrogen, Me, hydroxymethyl, or fluoromethyl; R7 is hydrogen, alkyl, alkynyl, halogen, cyano, carboxy, alkyloxycarbonyl, azido, amino, alkylamino, di(alkyl)amino, hydroxy, alkoxy, alkylthio, alkylsulfonyl; R8 is H, CN, nitro, alkyl, NHCONH₂, amide, thioamide, ester, C(=NH)NH₂, hydroxy, alkoxy, amino, alkylamino, di(alkyl)amino, halogen, (1,3-oxazol-2-yl), (1,3-thiazol-2-yl), or (imidazol-2-yl); alkyl is unsubstituted or substituted with one to three groups independently selected from halogen, amino, hydroxy, carboxy, and alkoxy; R9 is H, OH, SH, halogen, alkoxy, alkylthio, alkylcarbonyloxy, cycloalkylcarbonyloxy, alkyloxycarbonyloxy, cycloalkyloxycarbonyloxy, OCH₂CH₂SC(=O)alkyl, OCH₂O(C=O)alkyl, OCH(alkyl)O(C=O)alkyl, amino, alkylamino, cycloalkylamino; R10 is hydrogen, hydroxy, halogen, alkoxy, amino, alkylamino, cycloalkylamino; and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 4-amino-7-[2-C-methyl-3,5-di-O-(1-oxo-octyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine was prepared and tested as antiviral agent and inhibitor of RNA-dependent RNA viral polymerase.

IT 582313-35-7P 582313-51-7P 643032-23-9P
643032-24-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of nucleoside derivs. as antiviral agents and inhibitors of RNA-dependent RNA viral polymerase)

10/602,142

RN 582313-35-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-3-O-(1-oxooctyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 582313-51-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-3,5-bis-O-(1-oxooctyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 643032-23-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-5-O-(1-oxooctyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 643032-24-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-2,3,5-tris-O-(1-oxooctyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 443642-29-3P 443642-32-8P 443642-33-9P

582313-43-7P 582313-45-9P 582313-47-1P

582313-49-3P 582313-53-9P 582313-55-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nucleoside derivs. as antiviral agents and inhibitors of RNA-dependent RNA viral polymerase)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 443642-32-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 582313-43-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-((1,1-dimethylethyl)dimethylsilyl)-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 582313-45-9 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-((1,1-

McIntosh

10/602,142

dimethylethyl)dimethylsilyl]-2-C-methyl- β -D-ribofuranosyl]-N-[(4-methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 582313-47-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-C-methyl-3-O-(1-oxooctyl)- β -D-ribofuranosyl]-N-[(4-methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 582313-49-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-C-methyl-3-O-(1-oxooctyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 582313-53-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(4-methoxyphenyl)diphenylmethyl]-7-[2-C-methyl-3-O-(1-oxooctyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 582313-55-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(4-methoxyphenyl)diphenylmethyl]-7-[2-C-methyl-3,5-bis-O-(1-oxooctyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:20697 CAPLUS
 DN 140:87662
 TI 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections
 IN Sommadossi, Jean-pierre; La Colla, Paolo; Storer, Richard; Gosselin, Gilles
 PA Idenix (Cayman) Limited, Cayman I.; Centre National de la Recherche Scientifique; Universita Degli Studi di Cagliari
 SO PCT Int. Appl., 2498 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004003000	A2	20040108	WO 2003-IB3901	20030627
WO 2004003000	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490200	AA	20040108	CA 2003-2490200	20030627
AU 2003263412	A1	20040119	AU 2003-263412	20030627
EP 1525209	A2	20050427	EP 2003-761749	20030627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1678621	A	20051005	CN 2003-820690	20030627
JP 2005537242	T2	20051208	JP 2004-517162	20030627
CN 1761677	A	20060419	CN 2003-820501	20030627
WO 2005020884	A2	20050310	WO 2004-US15395	20040514
WO 2005020884	A3	20060622		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

EP 1656093 A2 20060517 EP 2004-776022 20040514
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 NO 2005000466 A 20050323 NO 2005-466 20050127

PRAI US 2002-392350P P 20020628
 US 2002-392351P P 20020628
 US 2003-466194P P 20030428
 US 2003-470949P P 20030514
 WO 2003-IB3901 W 20030627
 WO 2004-US15395 W 20040514

OS MARPAT 140:87662

AB 2' And 3'-Prodrugs of 1'-, 2'-, 3'-, or 4'-branched β -D or β -L
 nucleosides, or their pharmaceutically acceptable salts and derivs., are
 described which are useful in the prevention and treatment of Flaviviridae
 infections and other related conditions. These modified nucleosides
 provide superior results against flaviviruses and pestiviruses,
 including hepatitis C virus and viruses generally that
 replicate through an RNA-dependent RNA reverse transcriptase. Compds.,
 compns., methods and uses are provided for the treatment of Flaviviridae
 infection, including HCV infection, that include the
 administration of an effective amount of the prodrugs of the invention, or
 their pharmaceutically acceptable salts or derivs. These drugs may
 optionally be administered in combination or alternation with further
 antiviral agents to prevent or treat Flaviviridae infections and
 other related conditions. Preparation of compds. of the invention is included.


IT 443642-29-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (nucleoside prodrugs for treating Flaviviridae infections, and use with
 other agents)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AN 2003:1006709 CAPLUS
 DN 140:35898
 TI Carbocyclic nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
 IN Bhat, Balkrishen; Bhat, Neelima; Dande, Prasad; Eldrup, Anne B.; Olsen, David B.; MacCoss, Malcolm
 PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 46

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003105770	A2	20031224	WO 2003-US18841	20030614
	WO 2003105770	A3	20041007		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2488842	AA	20031224	CA 2003-2488842	20030614
	AU 2003251524	A1	20031231	AU 2003-251524	20030614
	EP 1515971	A2	20050323	EP 2003-760371	20030614
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005533777	T2	20051110	JP 2004-512678	20030614
PRAI	US 2002-389161P	P	20020617		
	WO 2003-US18841	W	20030614		

OS MARPAT 140:35898

AB The present invention provides carbocyclic nucleoside compds. and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such carbocyclic nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the carbocyclic nucleoside compds. of the present invention. HCV NS5B polymerase was inhibited with IC50's less than 100 µM.

IT 636583-00-1P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (carbocyclic nucleoside derivs. as inhibitors of RNA-dependent RNA viral polymerase)


RN 636583-00-1 CAPLUS

CN 1,2-Cyclopentanediol, 5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-

10/602,142


(hydroxymethyl)-1-methyl-, (1S,2R,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 636582-99-5 636583-05-6 636583-06-7
636583-15-8 636583-15-8D, pharmaceutically-acceptable
salts 636583-16-9 636583-16-9D, pharmaceutically-
acceptable salts 636583-21-6 636583-21-6D,
pharmaceutically-acceptable salts 636583-22-7
636583-22-7D, pharmaceutically-acceptable salts
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carbocyclic nucleoside derivs. as inhibitors of RNA-dependent RNA
viral polymerase)
RN 636582-99-5 CAPLUS
CN 1,2-Cyclopentanediol, 5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-
(hydroxymethyl)-1-methyl-, (2R,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636583-05-6 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[(1R,3R,4R)-2,3-dihydroxy-4-
(hydroxymethyl)-2-methylcyclopentyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 636583-06-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-2-methylcyclopentyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636583-15-8 CAPLUS

CN Triphosphoric acid, P-[[[(1R,2R,4R)-4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 636583-15-8 CAPLUS

CN Triphosphoric acid, P-[[[(1R,2R,4R)-4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 636583-16-9 CAPLUS

CN Triphosphoric acid, P-[[[(1R,2R,3S,4R)-4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 636583-16-9 CAPLUS

CN Triphosphoric acid, P-[[[(1R,2R,3S,4R)-4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl] ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 636583-21-6 CAPLUS


CN Triphosphoric acid, P-[[[(1R,2R,4R)-4-(2-amino-1,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl]

McIntosh

10/602,142

ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636583-21-6 CAPLUS

CN Triphosphoric acid, P-[[[(1R,2R,4R)-4-(2-amino-1,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 636583-22-7 CAPLUS

CN Triphosphoric acid, P-[[[(1R,2R,3S,4R)-4-(2-amino-1,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 636583-22-7 CAPLUS

CN Triphosphoric acid, P-[[[(1R,2R,3S,4R)-4-(2-amino-1,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-3-methylcyclopentyl]methyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 636583-32-9P 636583-33-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(carbocyclic nucleoside derivs. as inhibitors of RNA-dependent RNA viral polymerase)

RN 636583-32-9 CAPLUS

CN 1,2-Cyclopentanediol, 5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-(hydroxymethyl)-1-methyl-, (1R,2R,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 636583-33-0 CAPLUS


CN 1,2-Cyclopentanediol, 5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-(hydroxymethyl)-1-methyl-, (1S,2R,3R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/602,142

AN 2003:697043 CAPLUS
 DN 139:230954
 TI Preparation of nucleotide mimics and their prodrugs as antiviral
 , antibacterial, and antitumor agents
 IN Cook, Phillip Dan; Wang, Guangyi; Bruice, Thomas W.; Boyle, Nicholas A.;
 Leeds, Janet M.; Brooks, Jennifer L.; Prhavc, Marija; Ariza, Maria
 Eugenia; Fagan, Patrick C.; Jin, Yi; Rajwanshi, Vivek K.; Tucker, Kathleen
 D.
 PA Biota, Inc., USA
 SO PCT Int. Appl., 184 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003072757	A2	20030904	WO 2003-US6368	20030228
	WO 2003072757	A3	20040722		
	WO 2003072757	C2	20041021		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2477741	AA	20030904	CA 2003-2477741	20030228
	AU 2003217863	A1	20030909	AU 2003-217863	20030228
	US 2004059104	A1	20040325	US 2003-376654	20030228
	EP 1485395	A2	20041215	EP 2003-713832	20030228
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005525358	T2	20050825	JP 2003-571445	20030228
PRAI	US 2002-360699P	P	20020228		
	US 2002-360915P	P	20020228		
	WO 2003-US6368	W	20030228		
OS	MARPAT 139:230954				
GI					



AB. Nucleotide diphosphate mimics and nucleotide triphosphate mimics I,
 wherein A is O, S, NH, NR; R4' is LR5; L is O, S, NH, NR, CY2O, CY3S,
 CY2NH, CY2, CY2CY2, CY2OCY2, CY2SCY2, CY2NHCY2; Y is H, halogen, alkyl,
 alkenyl, alkynyl, R5 is substituted di- or triphosphate; R is alkyl,

McIntosh

alkenyl, alkynyl, aryl, acyl, aralkyl; R1-R4 and R2'-R3' are independently H, halogen, OH, SH, NH₂, NHOH, N₃, NO₂, CHO, CO₂H, CN, CONH₂, CO₂R, R, OR, SR, SSR, NHR, NR₂; D is nucleobase, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications were prepared as antiviral, antibacterial, and antitumor agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compns. comprising the compds. of the present invention optionally in combination with other pharmaceutically active agents. Thus, 3'-azido-3'-deoxythymidine 5'-α-P-borano-β,γ-(difluoromethylene)triphosphate was prepared and tested in vitro as antiviral, antibacterial, and antitumor agent and HIV reverse transcriptase inhibitor (K_i = 0.008-0.061 μM).


IT 591752-23-7P 591752-50-0P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleotide mimics and their prodrugs as antiviral antibacterial and antitumor agents)

RN 591752-23-7 CAPLUS


CN Borate(4-), [7-[5-O-[(1R)-4,4-difluoro-1,3,5,5-tetrahydroxy-3,5-dioxido-2-oxa-1,3,5-triphosphapent-1-yl-κP1]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-aminato(4-)]trihydro-, tetrahydrogen, (T-4)-(9CI) (CA INDEX NAME)



● 4 H⁺

RN 591752-50-0 CAPLUS

CN Borate(4-), [7-[5-O-[(1S)-4,4-difluoro-1,3,5,5-tetrahydroxy-3,5-dioxido-2-oxa-1,3,5-triphosphapent-1-yl-κP1]-2-C-methyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-aminato(4-)]trihydro-, tetrahydrogen, (T-4)-(9CI) (CA INDEX NAME)



● 4 H⁺


IT 591220-78-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nucleotide mimics and their prodrugs as antiviral antibacterial and antitumor agents)

RN 591220-78-9 CAPLUS

CN Acetamide, N-[7-(2,3-di-O-acetyl-2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 443642-29-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of nucleotide mimics and their prodrugs as antiviral antibacterial and antitumor agents)

RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L6 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:656596 CAPLUS
 DN 139:191380
 TI Methods of inhibiting orthopoxvirus replication with nucleoside compounds
 IN Olsen, David B.; Lafemina, Robert L.; Eldrup, Anne B.; Bera, Sanjib
 PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003068244	A1	20030821	WO 2003-US3703	20030207
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2474563	AA	20030821	CA 2003-2474563	20030207
AU 2003209045	A1	20030904	AU 2003-209045	20030207
EP 1476169	A1	20041117	EP 2003-707772	20030207
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005164960	A1	20050728	US 2003-504445	20030207
JP 2005527499	T2	20050915	JP 2003-567425	20030207
PRAI US 2002-356805P	P	20020213		
WO 2003-US3703	W	20030207		

OS MARPAT 139:191380

AB The present invention provides methods of inhibiting orthopoxvirus replication and/or treating orthopoxvirus infection with certain nucleoside compds. and derivs. thereof. These compds. are particularly useful as inhibitors of vaccinia virus and variola virus replication and/or for the treatment of vaccinia virus and variola virus infection. The nucleoside compds. may be administered alone or in combination with other agents active against orthopoxvirus infection, in particular against vaccinia virus or variola virus infection. Another aspect of the present invention provides for the use of such nucleoside compds. in the manufacture of a medicament for the inhibition of orthopoxvirus replication and/or for

the treatment of orthopoxvirus infection. Yet a further aspect of the present invention provides such nucleoside compds. for use as a medicament for the inhibition of orthopoxvirus replication and/or for the treatment of orthopoxvirus infection.


IT 141232-24-8P 443642-29-3P 443642-96-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(inhibiting orthopoxvirus replication with nucleoside compds.)

RN 141232-24-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 443642-96-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 139209-26-0P 443642-28-2P 443642-34-0P
 443642-38-4P 443642-41-9P 443642-42-0P
 443642-43-1P 443642-44-2P 443642-45-3P
 443642-46-4P 443642-47-5P 443642-48-6P
 443642-49-7P 443642-53-3P 443642-56-6P
 443642-57-7P 443642-60-2P 443642-63-5P
 443642-66-8P 443642-67-9P 443642-80-6P
 443642-83-9P 443642-86-2P 443642-87-3P
 443642-88-4P 443642-97-5P 443643-17-2P
 582313-35-7P 582313-51-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibiting orthopoxvirus replication with nucleoside compds.)

RN 139209-26-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-28-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-beta-D-arabinofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-34-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-38-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-41-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-cyclopropyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-42-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-43-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny]l]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-44-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyloxy]phosphinyloxy]phosphonyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-45-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-46-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-chloro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-47-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-bromo-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-48-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-49-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-(2-C-methyl-2-O-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-53-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-methyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-56-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxylic acid, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-57-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethenyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-60-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(hydroxymethyl)-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-63-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(fluoromethyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-66-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-2-C-methyl-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-67-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-2-C-methyl-β-D-threo-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-80-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-3-fluoro-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-83-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-2-O-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-86-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-87-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N,N-dimethyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-88-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-cyclopropyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-97-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 2-fluoro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443643-17-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-fluoro-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 582313-35-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-3-O-(1-oxooctyl)-β-D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 582313-51-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-methyl-3,5-bis-O-(1-oxooctyl)-β-D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh

10/602,142



IT 443642-32-8P 443642-33-9P 443642-36-2P
443642-37-3P 443642-39-5P 443642-40-8P
443642-50-0P 443642-51-1P 443642-52-2P
443642-54-4P 443642-55-5P 443642-58-8P
443642-62-4P 443642-64-6P 443642-65-7P
443642-84-0P 443642-85-1P 582313-25-5P
582313-26-6P 582313-43-7P 582313-45-9P
582313-47-1P 582313-49-3P 582313-53-9P
582313-55-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(inhibiting orthopoxvirus replication with nucleoside compds.)

RN 443642-32-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-36-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-ethyl-beta-D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-37-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-ethyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443642-39-5 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-beta-D-ribofuranosyl]-4-chloro- (9CI)

McIntosh

10/602,142

(CA INDEX NAME)


Absolute stereochemistry.



RN 443642-40-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-50-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro-5-methyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-51-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-52-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-1,7-dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-54-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-55-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-methyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443642-58-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-ethenyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-62-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(hydroxymethyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-64-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(fluoromethyl)- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-65-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(fluoromethyl)-β-D-ribofuranosyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry..




RN 443642-84-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-85-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 582313-25-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-ethenyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 582313-26-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[2-C-(hydroxymethyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 582313-43-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 582313-45-9 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(1,1-

McIntosh

10/602,142

dimethylethyl)dimethylsilyl]-2-C-methyl- β -D-ribofuranosyl]-N-[(4-methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 582313-47-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-C-methyl-3-O-(1-oxooctyl)- β -D-ribofuranosyl]-N-[(4-methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 582313-49-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-C-methyl-3-O-(1-oxooctyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 582313-53-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(4-methoxyphenyl)diphenylmethyl]-7-[2-C-methyl-3-O-(1-oxooctyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 582313-55-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-[(4-methoxyphenyl)diphenylmethyl]-7-[2-C-methyl-3,5-bis-O-(1-oxooctyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:590940 CAPLUS
DN 139:133787
TI Preparation of deazapurine nucleoside analogs as antiviral agents
IN An, Haoyun; Ding, Yili; Chamakura, Varaprasad; Hong, Zhi
PA Ribapharm Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003061576	A2	20030731	WO 2003-US1545	20030117
WO 2003061576	A3	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003209285	A1	20030902	AU 2003-209285	20030117
PRAI US 2002-350296P	P	20020117		
WO 2003-US1545	W	20030117		
OS MARPAT 139:133787				
GI				



- AB Methods, compns., and uses for various deazapurine nucleoside libraries and library compds. I are provided. Particularly preferred deazapurine nucleosides include 7-deazapurine nucleosides, 7-deaza-8-azapurine nucleosides, toyocamycin nucleoside analogs, 3-deazapurine nucleosides, and 9-deazapurine nucleosides, while preferred uses especially include use of such compds. as pharmacol., and particularly antiviral agents. 4-N,N-dimethylamino-7-(β -D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-N-hydroxycarbamide was prepared and tested in vitro as antiviral agent.
- IT 565455-20-1P 565455-21-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of deazapurine nucleoside analogs as antiviral agents)
- RN 565455-20-1 CAPLUS
- CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-(methylamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



- RN 565455-21-2 CAPLUS
- CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, 4-(dimethylamino)-N-hydroxy-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/602,142




IT 565455-24-5 565455-25-6 565455-26-7
565455-27-8 565455-28-9 565455-29-0
565455-30-3 565455-31-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of deazapurine nucleoside analogs as antiviral
agents)

RN 565455-24-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, 4,7-dihydro-N-hydroxy-7-(2-
C-methyl- β -D-ribofuranosyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 565455-25-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, 4-amino-N-hydroxy-7-(2-C-
methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 565455-26-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-(hydroxyamino)-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 565455-27-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, 4-(hydroxyamino)-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 565455-28-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, N-hydroxy-4-(hydroxyamino)-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 565455-29-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-(hydroxyamino)-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 565455-30-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-7-(2-C-methyl-beta-D-ribofuranosyl)-4-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 565455-31-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-hydrazino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 141232-24-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of deazapurine nucleoside analogs as antiviral agents)

RN 141232-24-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 565455-17-6P 565455-18-7P 565455-19-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of deazapurine nucleoside analogs as antiviral agents)


RN 565455-17-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4,7-dihydro-4-oxo-7-(2,3,5-tri-O-acetyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 565455-18-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-chloro-7-(2,3,5-tri-O-acetyl-2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 565455-19-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-(methyldamino)-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:590902 CAPLUS

DN 139:127989

TI Tricyclic nucleoside derivatives for use as antiviral agents

IN An, Haoyun; Hong, Zhi; Smith, Kenneth; Ding, Yili; Girardet, Jean-luc

PA Ribapharm Inc., USA

SO PCT Int. Appl., 65 pp.

McIntosh

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003061385	A1	20030731	WO 2002-US31369	20021001
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-350249P	P	20020117		
	US 2002-395241P	P	20020710		
OS	MARPAT 139:127989				
AB	Tricyclic nucleoside libraries and library compds. are prepared using combinatorial chemical and non-combinatorial chemical methods. Contemplated library compds. are particularly useful in inhibition of viral propagation, and particularly of viral propagation of the HCV virus. Thus, 6-amino-8-(β -D-ribofuranosyl)-4-methylpyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine (tricitribin) was synthesized. This inhibited hepatitis C virus in Huh-7 cells with EC ₅₀ of <10 μ M.				
IT	566152-71-4P 566152-73-6P 566152-75-8P RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (tricyclic nucleoside derivs. for use as antiviral agents)				
RN	566152-71-4 CAPLUS				
CN	1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 566152-73-6 CAPLUS

 CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 5-ethyl-1,5-dihydro-1-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

10/602,142


Absolute stereochemistry.



RN 566152-75-8 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-1-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 141232-24-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(tricyclic nucleoside derivs. for use as antiviral agents)

RN 141232-24-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

10/602,142

IT 565455-17-6P 565455-18-7P 566152-70-3P
566152-72-5P 566152-74-7P 566152-77-0P
566152-78-1P 566152-79-2P 566152-80-5P
566152-81-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(tricyclic nucleoside derivs. for use as antiviral agents)

RN 565455-17-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4,7-dihydro-4-oxo-7-(2,3,5-tri-O-acetyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 565455-18-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-chloro-7-(2,3,5-tri-O-acetyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 566152-70-3 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(2,3,5-tri-O-acetyl-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 566152-72-5 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylene-3-amine, 5-ethyl-1,5-dihydro-1-(2,3,5-tri-O-acetyl-2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 566152-74-7 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylene-3-amine, 1,5-dihydro-1-(2-C-methyl-beta-D-ribofuranosyl)-5-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 566152-77-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-6-bromo-7-[2-C-methyl-2,3,5-tris-O-(phenylmethyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 566152-78-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-[2-C-methyl-2,3,5-tris-O-(phenylmethyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 566152-79-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4,7-dihydro-7-[2-C-methyl-2,3,5-tris-O-(phenylmethyl)- β -D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 566152-80-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-chloro-7-[2-C-methyl-2,3,5-tris-O-(phenylmethyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 566152-81-6 CAPLUS

CN 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-1-[2-C-methyl-2,3,5-tris-O-(phenylmethyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:555629 CAPLUS

DN 137:125359

TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

IN Carroll, Steven S.; Lafemina, Robert L.; Hall, Dawn L.; Himmelberger, Amy L.; Kuo, Lawrence C.; Maccoss, Malcolm; Olsen, David B.; Rutkowski, Carrie A.; Tomassini, Joanne E.; An, Haoyun; Bhat, Balkrishen; Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.; Guinosso, Charles J.; Prhavc, Marija; Prakash, Thazha P.

PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.

SO PCT Int. Appl., 235 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.

KIND


DATE

APPLICATION NO.

DATE

McIntosh

PI	WO 2002057425	A2	20020725	WO 2002-US1531	20020118
	WO 2002057425	A3	20050421		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2433878	AA	20020725	CA 2002-2433878	20020118
	US 2002147160	A1	20021010	US 2002-52318	20020118
	US 6777395	B2	20040817		
	CN 1498221	A	20040519	CN 2002-806977	20020118
	JP 2004532184	T2	20041021	JP 2002-558479	20020118
	EP 1539188	A2	20050615	EP 2002-709095	20020118
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2004072788	A1	20040415	US 2003-431657	20030507
	ZA 2003005078	A	20040521	ZA 2003-5078	20030630
	US 2004067901	A1	20040408	US 2003-688691	20031017
	US 2004110717	A1	20040610	US 2004-250873	20040116
	US 2005272676	A1	20051208	US 2005-200499	20050809
PRAI	US 2001-263313P	P	20010122		
	US 2001-282069P	P	20010406		
	US 2001-299320P	P	20010619		
	US 2001-344528P	P	20011025		
	US 2002-52318	A3	20020118		
	WO 2002-US1531	W	20020118		
	US 2003-431657	B1	20030507		
OS	MARPAT 137:125359				
GI					



AB The present invention provides the preparation of nucleoside compds. I, wherein B is nucleobase, Y is H, alkylcarbonyl, phosphate; R1 is H, alkenyl, alkynyl, alkyl; R2 and R3 are independently H, OH, halogen, alkyl, alkoxy, alkenyloxy, alkylthio, alkylcarbonyloxy, aryloxyrcrbonyl, azido, amino, alkylamino; R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered heterocycle; R4 is H, OH, SH, NH2, alkylamino, cycloalkylamino, halogen, alkyl, alkoxy, CF3; R5 and R6 are independently H, hydroxymethyl, Me, fluoromethyl; and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B

polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 4-amino-1-(2-C-methyl- β -D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine was prepared as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the HCV NS5B polymerase assay exhibited IC's less than 100 μ M. The compds. of the present invention were also evaluated for their ability to affect the replication of Hepatitis C Virus RNA in cultured hepatoma (HuH-7) cells containing a sub-genomic HCV Replicon.

IT 139209-26-0P 141232-24-8P 443642-28-2P
 443642-29-3P 443642-34-0P 443642-38-4P
 443642-41-9P 443642-42-0P 443642-43-1P
 443642-44-2P 443642-45-3P 443642-46-4P
 443642-47-5P 443642-48-6P 443642-49-7P
 443642-53-3P 443642-56-6P 443642-57-7P
 443642-60-2P 443642-63-5P 443642-66-8P
 443642-67-9P 443642-80-6P 443642-83-9P
 443642-86-2P 443642-87-3P 443642-88-4P
 443642-96-4P 443642-97-5P 443642-98-6P
 443643-26-3P 443643-28-5P 444020-48-8P
 444020-89-7P 444020-90-0P 444020-91-1P
 444020-92-2P 444021-33-4P 444021-34-5P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

RN 139209-26-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 141232-24-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-28-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-arabinofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 443642-34-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-38-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-41-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-cyclopropyl-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-42-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-43-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-44-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-45-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-46-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-chloro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-47-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-bromo-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-48-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-49-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-(2-C-methyl-2-O-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-53-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-56-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxylic acid, 4-amino-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-57-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethenyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-60-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(hydroxymethyl)- β -D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-63-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(fluoromethyl)- β -D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-66-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-2-C-methyl-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-67-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-2-C-methyl-β-D-threo-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-80-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-3-fluoro-2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-83-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-2-O-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-86-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-87-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N,N-dimethyl-7-(2-C-methyl- β -D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-88-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-cyclopropyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-96-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-97-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 2-fluoro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-98-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-arabinofuranosyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 443643-26-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443643-28-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-ethyl-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 444020-48-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4-chloro-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444020-89-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444020-90-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-[2-C-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 444020-91-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444020-92-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 4-amino-7-[2-C-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444021-33-4 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4-chloro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

McIntosh

10/602,142

β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-34-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4-chloro-7-[2-C-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 443642-32-8P 443642-33-9P 443642-36-2P
443642-37-3P 443642-39-5P 443642-40-8P
443642-50-0P 443642-51-1P 443642-52-2P
443642-54-4P 443642-55-5P 443642-58-8P
443642-61-3P 443642-64-6P 443642-84-0P
443642-85-1P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)


RN 443642-32-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-36-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-ethyl-beta-D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443642-37-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-ethyl- β -D-ribofuranosyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-39-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 443642-40-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-50-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-51-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-52-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-1,7-dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-54-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-55-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-methyl-7-(2-C-methyl-β-D-ribofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-58-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-ethenyl-β-D-ribofuranosyl]-4-chloro-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443642-61-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(hydroxymethyl)- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-64-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(fluoromethyl)- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-84-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/602,142



RN 443642-85-1 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:555511 CAPLUS
DN 137:109450
TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
IN Carroll, Steven S.; Maccoss, Malcolm; Olsen, David B.; Bhat, Balkrishen; Bhat, Neelima; Cook, Phillip Dan; Eldrup, Anne B.; Prakash, Thazha P.; Prhavc, Marija; Song, Quanlai
PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

McIntosh

PI	WO 2002057287	A2	20020725	WO 2002-US3086	20020118
	WO 2002057287	A3	20021010		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2434386	AA	20020825	CA 2002-2434386	20020118
	US 2002147160	A1	20021010	US 2002-52318	20020118
	US 6777395	B2	20040817		
	EE 200300338	A	20031015	EE 2003-338	20020118
	EP 1355916	A2	20031029	EP 2002-709299	20020118
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2002006614	A	20040217	BR 2002-6614	20020118
	CN 1498221	A	20040519	CN 2002-806977	20020118
	JP 2004520367	T2	20040708	JP 2002-557963	20020118
	NZ 526703	A	20041224	NZ 2002-526703	20020118
	US 2004072788	A1	20040415	US 2003-431657	20030507
	ZA 2003005078	A	20040521	ZA 2003-5078	20030630
	BG 108000	A	20040831	BG 2003-108000	20030717
	NO 2003003289	A	20030919	NO 2003-3289	20030721
	US 2004067901	A1	20040408	US 2003-688691	20031017
	US 2005272676	A1	20051208	US 2005-200499	20050809
PRAI	US 2001-263313P	P	20010122		
	US 2001-282069P	P	20010406		
	US 2001-299320P	P	20010619		
	US 2001-344528P	P	20011025		
	US 2002-52318	A3	20020118		
	WO 2002-US3086	W	20020118		
	US 2003-431657	B1	20030507		
OS	MARPAT 137:109450				
GI					



I

AB The present invention provides nucleoside compds. I, wherein R1 is

alkenyl, alkynyl, alkyl, wherein alkyl is unsubstituted or substituted with hydroxy, amino, alkoxy, alkylthio, one to three fluorine atoms; R2 is hydrogen, fluorine, hydroxy, mercapto, alkoxy, alkyl; or R1 and R2 together with the carbon atom to which they are attached form a 3- to 6-membered saturated monocyclic ring system optionally containing a heteroatom selected from O, S, and NC-alkyl; R3 and R4 are each independently hydrogen, cyano, azido, halogen, hydroxy, mercapto, amino, alkoxy, alkenyl, alkynyl, alkyl; R5 is hydrogen, alkylcarbonyl, phosphate; R6 and R7 are each independently hydrogen, Me, hydroxymethyl, or fluoromethyl; R8 is hydrogen, alkyl, alkynyl, halogen, cyano, carboxy, alkyloxycarbonyl, azido, amino, alkylamino, di(alkyl)amino, hydroxy, alkoxy, alkylthio, alkylsulfonyl, alkylaminomethyl, cycloheteroalkyl; R9 is hydrogen, cyano, nitro, alkyl, NHCONH2, amide, thioamide, ester, C(=NH)NH2, hydroxy, alkoxy, amino, alkylamino, di(alkyl)amino, halogen, (1,3-oxazol-2-yl), (1,3-thiazol-2-yl), or (imidazol-2-yl); R10 and R11 are each independently hydrogen, hydroxy, halogen, alkoxy, amino, alkylamino, di(alkyl)amino, cycloalkylamino, di(cycloalkyl)amino, cycloheteroalkyl, and certain derivs. thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such nucleoside compds. alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compds. of the present invention. Thus, 4-amino-7-(2-C-methyl-β-D-arabinofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine was prepared as inhibitors of RNA-dependent RNA viral polymerase. Representative compds. tested in the HCV NS5B polymerase assay exhibited IC's less than 100 μM. The nucleoside derivs. were also screened for cytotoxicity against cultured hepatoma (HuH-7) cells containing a sub-genomic HCV Replicon in an MTS cell-based assay.

IT 443642-28-2P 443642-34-0P 443642-38-4P
 443642-41-9P 443642-42-0P 443642-43-1P
 443642-44-2P 443642-45-3P 443642-46-4P
 443642-47-5P 443642-48-6P 443642-49-7P
 443642-53-3P 443642-56-6P 443642-57-7P
 443642-60-2P 443642-63-5P 443642-66-8P
 443642-67-9P 443642-80-6P 443642-83-9P
 443642-86-2P 443642-87-3P 443642-88-4P
 443642-97-5P 443642-98-6P 443642-99-7P
 443643-00-3P 443643-01-4P 443643-04-7P
 443643-07-0P 443643-09-2P 443643-11-6P
 443643-13-8P 443643-15-0P 443643-16-1P
 443643-17-2P 443643-18-3P 443643-20-7P
 443643-22-9P 443643-24-1P 443643-26-3P
 443643-28-5P 443643-29-6P 443643-30-9P
 443643-31-0P 443643-32-1P 443643-33-2P
 443643-34-3P 443643-37-6P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

10/602,142

RN 443642-28-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-arabinofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-34-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-38-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443642-41-9 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-cyclopropyl-7-(2-C-methyl-

McIntosh

10/602,142

β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-42-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-5-O-phosphono- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-43-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy(phosphonooxy)phosphiny]l]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443642-44-2 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[hydroxy(phosphonooxy)]phosphiny]l]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

McIntosh

10/602,142

phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-45-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-46-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-chloro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-47-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-bromo-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 443642-48-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-49-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-(2-C-methyl-2-O-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-53-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-methyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-56-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxylic acid, 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-57-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-ethenyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-60-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(hydroxymethyl)-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-63-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(fluoromethyl)-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-66-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-2-C-methyl-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-67-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-2-C-methyl-β-D-threo-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-80-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(3-deoxy-3-fluoro-2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-83-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-2-O-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-86-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-7-(2-C-methyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-87-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N,N-dimethyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-88-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-cyclopropyl-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-97-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 2-fluoro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-98-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-arabinofuranosyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 443642-99-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443643-00-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443643-01-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-cyclopropyl-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-04-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-ethenyl-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443643-07-0 CAPLUS


CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-(hydroxymethyl)-beta-D-ribofuranosyl]-

McIntosh

10/602,142

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-09-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-(fluoromethyl)-5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-11-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443643-13-8 CAPLUS

McIntosh

10/602,142

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxylic acid, 4-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-15-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-bromo-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-16-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-chloro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443643-17-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-fluoro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-18-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-fluoro-7-[5-O-[hydroxy[(hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-20-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[5-O-[hydroxy[(hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl]-2-C-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443643-22-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-24-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-cyclopropyl-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-26-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443643-28-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[2-C-ethyl-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-29-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-30-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443643-31-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-2-O-methyl- β -D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-32-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-33-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl- β -D-threo-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443643-34-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 2-fluoro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443643-37-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3-deoxy-3-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-C-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 141232-24-8P 443642-29-3P 443642-32-8P
443642-33-9P 443642-36-2P 443642-37-3P
443642-39-5P 443642-40-8P 443642-50-0P
443642-51-1P 443642-52-2P 443642-54-4P
443642-55-5P 443642-58-8P 443642-61-3P
443642-62-4P 443642-64-6P 443642-65-7P
443642-84-0P 443642-85-1P 443642-96-4P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)


RN 141232-24-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 4-amino-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-29-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl- β -D-ribofuranosyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 443642-32-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-33-9 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

McIntosh

10/602,142


Absolute stereochemistry.



RN 443642-36-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-ethyl-beta-D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-37-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-C-ethyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443642-39-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 443642-40-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 4-chloro-7-(2-C-methyl- β -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-50-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl- β -D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-51-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-52-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-1,7-dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-54-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-β-D-ribofuranosyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-55-5 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-5-methyl-7-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/602,142

RN 443642-58-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-ethenyl- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 443642-61-3 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(hydroxymethyl)- β -D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-62-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(hydroxymethyl)- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/602,142



RN 443642-64-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(fluoromethyl)-β-D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-65-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-(fluoromethyl)-β-D-ribofuranosyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-84-0 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 443642-85-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[3,5-bis-O-[(2,4-dichlorophenyl)methyl]-2-C-methyl-2-O-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/602,142



RN 443642-96-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-(2-C-methyl-beta-D-ribofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:457887 CAPLUS

DN 121:57887

TI 2'-deoxy-2',2'-difluoro-(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates

IN Grindley, Gerald Burr; Grossman, Cora Sue; Hertel, Larry Wayne; Kroin, Julian Stanley

PA Eli Lilly and Co., USA

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 576227	A2	19931229	EP 1993-304815	19930621
	EP 576227	A3	19940209		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9341347	A1	19931223	AU 1993-41347	19930618
	CA 2098876	AA	19931223	CA 1993-2098876	19930621
	NO 9302287	A	19931223	NO 1993-2287	19930621

McIntosh

10/602,142

BR 9302433	A	19940111	BR 1993-2433	19930621
HU 64553	A2	19940128	HU 1993-1821	19930621
JP 06056877	A2	19940301	JP 1993-149191	19930621
CN 1084178	A	19940323	CN 1993-107740	19930621
PRAI US 1992-902304	A	19920622		
OS MARPAT 121:57887				
GI				



AB Title compds. I [B = purine, azapurine, deazapurine base] were prepared Thus, 2-amino-6-chloropurine was glycosidated, treated with MeNH₂, and deblocked to give I [B = 2-amino-6-methylaminopurine] which had an IC₅₀ against human leukemia cells of 0.054 µg/mL and caused 56.9% inhibition of hepatitis B in vitro at 0.1 µg/mL.

IT 156058-25-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of deoxydifluororibofuranosylpurine nucleosides)

RN 156058-25-2 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 156058-35-4P 156124-78-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)


RN 156058-35-4 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh

10/602,142



RN 156124-78-6 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-(3,5-di-O-benzoyl-2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

